










The handle http://hdl.handle.net/1887/35124 holds various files of this Leiden University 
dissertation. 
 
Author: Wokke, Beatrijs Henriette Aleid 
Title: Muscle MRI in Duchenne and Becker muscular dystrophy 




Muscle MRI in Duchenne  






























PhD Thesis, Leiden University Medical Center, Leiden 2015
ISBN: 978-94-6299-137-8
Author: Beatrijs Wokke
Cover design: Bilbo Schickenberg
Layout: Ridderprint BV - www.ridderprint.nl
Printed by: Ridderprint BV - www.ridderprint.nl
Financial support for the publication of this thesis was kindly provided by Philips 
Healthcare Netherlands.
The work in this thesis was supported by het Prinses Beatrix Spierfonds en Association 
Française contre les Myopathies.
Copyright of the individual chapter lies with the publisher of the journal listed at the 
beginning of each chapter.
No part of this thesis may be reproduced, stored or transmitted in any form or by any 
means, without prior permission of the author.
Muscle MRI in Duchenne  
and Becker muscular dystrophy
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 9 september 2015
klokke 16.15 uur
door Beatrijs Henriëtte Aleid Wokke
geboren te Haarlem in 1983
PRoMotIeCoMMIssIe
Promotor:





Prof. dr. J.L. Bloem
Dr. E.H. Niks
Prof. dr. V. Straub (Newcastle University, Newcastle, United Kingdom)
Lasciate ogne speranze, voi ch’intrate
Divine Comedy, Dante Alighieri (1265-1321)

Contents
Chapter 1 General introduction 9
Chapter 2 Comparison of Dixon and T1-weighted MR methods to 
assess the degree of fatty infiltration in Duchenne muscular 
dystrophy patients
21
J.Magn Reson Imaging 2013 Sep 38 (3) 619-24
Chapter 3 Quantitative MRI and strength measurements in the 
assessment of muscle quality in Duchenne muscular 
dystrophy
33
Neuromusc Disord 2014 May 24 (5) 409-16
Chapter 4 Dystrophin levels and clinical severity in Becker muscular 
dystrophy patients
47
J. Neurol Neurosurg Psychiatry 2014 Jul 85 (7) 747-53
Chapter 5 T2 relaxation times are increased in skeletal muscle of DMD 
but not BMD patients
65
Muscle Nerve 2015 Apr 6 doi:10.1002/musc.24679
Chapter 6 Muscle spectroscopy detects elevated PDE/ATP ratios prior to 
fatty infiltration in Becker muscular dystrophy patients
77
NMR Biomed 2014 Nov 27 (11) 1371-7
Chapter 7 Discussion and conclusion 91
Chapter 8 Summary 97
Nederlandse samenvatting 101
Appendices References 107
List of abbreviations 123



























































 1DuChenne AnD BeCkeR MusCulAR DystRoPhy: hIstoRICAl 
AsPeCts
In 1851 Edward Meryon published the first paper in which Duchenne muscular 
dystrophy (DMD) was reported as a disease entity. He described eight patients from 
three families with progressive muscle weakness and wasting, onset in early childhood 
and death in their late teens. He believed the disease to be hereditary and to have a 
predilection for males. By studying muscle tissue obtained post-mortem he observed 
that muscle tissue appeared to be primarily affected while the nervous system was still 
intact. He also described that the sarcolemma of the ‘elementary fibre’ was broken 
down and destroyed and that muscle fibres were converted into ‘granular and fatty mat-
ter’ [1, 2]. Several years later Guillaume Benjamin Amand Duchenne further studied 
patients with the same symptoms, describing progressive muscle weakness, initially 
affecting the lower limbs and eventually the upper limbs as well. He also observed 
a gradual increase in size of the affected muscles. He reported a gradual increase in 
interstitial connective tissue of affected muscles with age in muscle biopsies, with 
abundant fibrous and adipose tissue in later stages of the disease [3, 4]. In 1879, Gow-
ers described the well-known Gowers’ sign, that refers to the difficulty for patients to 
rise from the floor, due to hip and knee extensor weakness, and the compensatory use 
of arms to ‘climb up their body’ [5].
Several decades later, in the mid-1950s, Becker and Kiener described a ‘new X-
chromosomal muscular dystrophy’ [6]. They observed that these patients had a similar 
pattern of muscle involvement as DMD patients but a much slower rate of disease pro-
gression. This disease entity came to be known as Becker muscular dystrophy (BMD). 
As the disease phenotype of these patients was so similar to DMD patients, Becker 
and Kiener thought it likely that DMD and BMD were linked to the same gene. This 
was confirmed a few decades later, when DMD was mapped to the short arm of the 
X-chromosome and DMD and BMD were shown to be allelic [7-9]. In the late 1980s 
the product of the DMD gene, dystrophin, was shown to be associated with the muscle 
sarcolemma and lack of dystrophin was identified to be the primary biochemical defect 
in DMD patients [9-12].
ClInICAl PhenotyPe
DMD
DMD has an incidence of 1 in 4700 male live births and prevalence of 2.5 in 100.000 
[13, 14]. Patients generally present between the ages of two and four years with symp-
toms such as difficulty walking stairs, falling, a waddling gait, a tendency to walk 
Chapter 1
12
on tip-toe and difficulties rising from the floor [15-17]. Many patients have muscle 
enlargement, most notably of the calf muscles. Approximately 50% of DMD patients 
have some delay in motor milestones in terms of the age of walking and most patients 
are never able to run properly [17]. Muscle weakness is progressive with age, resulting 
in wheelchair dependency in patients’ early teens, loss of upper extremity function and 
frequent scoliosis [15, 18]. The respiratory muscles become progressively affected and 
respiratory failure is the main cause of death, although life expectancy has increased 
over the last decades with the accessibility of mechanical ventilation [19-21]. With 
age, cardiac muscle also becomes affected, mainly resulting in a dilated cardiomyopa-
thy [22]. Smooth muscle tissue can be involved as well, presenting as gastro-intestinal 
tract and bladder problems. Some patients have a delay in intellectual milestones and 
speech development and the intelligence quotient has been found to be one standard 
deviation below average compared to the general population [23-25]. Patients usually 
die in their mid-thirties following respiratory or cardiac failure [26].
BMD
The incidence of BMD is around 1 in 18.450 males and the prevalence 2.4 in 100.000 
[13, 27]. Overall BMD patients are less severely affected than DMD patients but show 
great variability in the severity of their clinical symptoms and rate of disease progres-
sion. While some patients lose mobility in their teens others experience only mildly 
progressive weakness during their adult life. Initial clinical presentation is usually 
in patients’ early teens, although some patients present many decades later, with the 
most common presenting symptoms being cramping muscle pains, falling, problems 
walking stairs and a waddling gait [28-30]. Frequently there is involvement of the 
cardiac muscle, which increases with age and is the cause of death in about half of 
patients [31, 32].
MusCle AnAtoMy
The skeletal muscle is surrounded by connective tissue called the epimysium and 
consists of muscle fascicles (encased with perimysium) build up from some or many 
muscle fibres or myocytes sheated by the endomysium. The myocytes are covered by 
the sarcolemma (inner plasma membrane) and outer basement membrane (Figure 1). 
The sarcoplasm is the cytoplasm of the muscle fibre and is composed of myofibrils 
and mitochondria and ribosomes. In the myofibril, protein filaments (myofilaments) 
are organized in repeating units named sarcomeres. These filaments include actin (thin 










There are several hypotheses about the pathogenic mechanisms to the progressive mus-
cle damage in DMD and BMD patients (Figure 2). A key causative factor is thought to 
be mechanical. Dystrophin is part of the multimeric dystrophin-glycoprotein complex 
(DGC) containing dystrobrevins, syntrophins, sarcoglycans and dystroglycans (Fig-
ure 1). The DGC mechanically links the extracellular matrix surrounding the muscle 
fibre to the sarcomere, providing structural stabilization of the muscle sarcolemma and 
is also involved in cell signalling [33-36]. The DGCs are localized at the sarcolemma 
Figure 1. Skeletal muscle fibre showing dystrophin as part of the dystrophin-glycoprotein complex.




in rib-like lattices named costameres which help transmit forces laterally to the basal 
lamina [35]. Dystrophin deficiency disrupts the costameric lattice, which increases 
susceptibility to contraction-induced injury [35, 37, 38]. In DMD patients dystrophin 
is absent as a mutation in the DMD gene disrupts the translational reading frame 
or introduces a premature stopcodon. In contrast, in most BMD patients mutations 
(generally deletions) maintain the translational reading frame and as such a shorter 
and internally deleted, partly functional, dystrophin protein can be produced [12, 39]. 
The difference between complete absence and partial absence of dystrophin function is 
likely to affect the amount of disruption in the structural integrity of the muscle. This 
could explain some of the variability between the two disease entities.
Calcium related damage
Another potential mechanism contributing to (secondary) muscle damage is an in-
crease in intracellular calcium. It has been hypothesized that stretch induced muscle 
damage induces increased intracellular calcium levels, however the exact underlying 
mechanism is unknown [40]. Increased intracellular calcium levels decrease the ability 
of the muscle to maintain physiological calcium levels and activate calcium-dependent 







 1proteases like calpain, which contribute to degradation of muscle membrane proteins 
and cause myonecrosis [41, 42]. Additionally, increased calpain levels may also cause 
abnormal mitochondrial function, resulting in cell death [43].
Vascular factors
Neuronal nitric oxide synthase (nNOS) is a dystrophin-associated protein and inter-
acts with spectrin-like repeats 16 and 17 within the rod-terminal of dystrophin and is 
recruited to the sarcolemma via α-syntrophin [44, 45]. nNOS produces nitric oxide 
(NO), which is an important factor in the reduction of sympathetic vasoconstriction 
in contracting muscle [46]. Dystrophin deficiency results in nNOS displacement from 
the sarcolemma to the myofiber cytosol and a reduction in its enzymatic activity [44, 
47, 48]. The loss of sarcolemmal nNOS renders the muscle prone to muscle ischemia 
during muscle contraction following failure of ‘normal’ NO-mediated vasodilatation 
[49, 50]. nNOS deficiency also results in NO-related pathology in terms of free radical 
production and oxidative stress, leading to further mitochondrial damage [51-53].
Inflammatory factors
Various studies have shown that there is inflammation in muscle tissue of both DMD 
and BMD patients [44, 54, 55]. However, whether the inflammatory reaction is pri-
mary or secondary and to what extent inflammation results in additional damage of the 
muscle fibres still remains debated [56-60]. While some have suggested that inflam-
mation is a result of non-specific inflammatory cell recruitment to sites of muscle 
fibre destruction [55, 59], others proposed that mechanisms such as a toll-like receptor 
mediated reaction, a specific cellular auto-immune response or involvement of mast 
cells could also contribute to the observed inflammation [55, 61-63].
Fatty infiltration and fibrosis
As a result of the ongoing muscle cell damage satellite cells become activated produc-
ing precursor cells, which differentiate into myoblasts contributing to the regenera-
tion of the injured myofibers. There is also an influx of inflammatory cells that can 
phagocytose the degenerated fibres. The capacity of the satellite cells to compensate 
the ongoing muscle damage progressively fails, also as consequence of the chronic 
inflammation. As a result muscle fibres are increasingly replaced by adipose and con-
nective tissue (Figure 3) [64, 65]. Although there are some signs of ongoing tissue 
damage in very young patients before onset of clinical weakness, the signs of muscle 




Since the discovery of the DMD gene there have been many studies looking for treat-
ments for DMD patients. Corticosteroids have been shown to increase muscle strength, 
delay loss of ambulation and appear to affect the progression of cardiac and respiratory 
function in DMD patients [66-71]. The underlying mechanism of this effect remains 
largely unknown and the side effects are considerable [72]. Other therapies include 
supportive therapies such as cardiac, respiratory management and rehabilitation [73, 
74]. Although no curative therapies are yet available, disease-modulating approaches 
including Idebenone, which aims to protect against mitochondrial dysfunction, and 
Myostatin antibodies aiming to increase muscle mass are currently being investigated. 
Translarna (Ataluren) interacts with the ribosome and allows the cell to ignore prema-
ture stop codons and produce functional proteins and has recently received conditional 
marketing approval and as such will become available to patients in the near future. 
Also, several ongoing studies focus on restoring expression of modified dystrophin [70, 
Figure 3. Muscle biopsies of DMD patient showing dystrophic features including fat replacement 








 175, 76]. These include exon skipping strategies, which use antisense oligonuceotides 
and aim to ameliorate the DMD into the BMD phenotype [77-79]. Although for BMD 
patients no disease modifying drugs are available, there are some, albeit less than in 
DMD, clinical trials for these patients. In BMD patients Tadalafil, a Phosphordiesterase 
(PDE) 5A inhibitor boosting NO, was shown to alleviate functional muscle ischaemia 
and restore blood flow in BMD patients [50]. However, recently the results of another 
study aiming to restore the effects of nNOS using a PDE 5 inhibitor (Sildenafil) were 
published and found no positive effects muscle blood flow or muscle performance 
[80]. Studies currently undertaken in BMD patients include the Follistatin gene, aim-
ing to increase muscle fibre size and strength.
MAGnetIC ResonAnCe IMAGInG In DMD AnD BMD
The first muscle imaging studies in DMD and BMD patients were ultrasound and 
computed tomography (CT) studies in the early eighties and nineties [81-86]. The 
initial magnetic resonance imaging (MRI) studies of muscles of DMD patients were 
published some years later. In these MRI studies a decrease in the muscle T1 relaxation 
time was described and believed to result from (progressive) fat replacement in the 
muscles. The changes were found to increase with age, to correlate well with the clini-
cal staging and to be neither uniform in all muscles nor within one muscle [87, 88]. 
Consequently, it was suggested that MRI could be of potential value in the diagnosis 
of DMD and staging of the disease. Additionally, as MRI provided multiplanar, high-
resolution images with good contrast between soft tissues without the use of ionizing 
radiation it was felt that MRI could be a preferable imaging method to CT [89].
As MRI is relatively easily accessible and non-invasive it was proposed as a promising 
method to assess disease progression and the efficacy of future therapeutic interventions 
in DMD patients [90, 91]. In the same period several magnetic resonance spectroscopy 
(MRS) studies were performed in DMD and BMD patients [92-97]. MRS can be used 
to assess muscle metabolites such as intra- and extramyocellular lipids, choline and 
creatine using proton (1H) -MRS and muscle energy dynamics using phosphorus (31P) 
MRS. These studies mainly focussed on energy metabolism and the effects of exercise. 
Although the results of these studies were not fully in agreement, generally there ap-
peared to be alterations in energy metabolism. These alterations included an increase 
in muscle pH and abnormal recovery of some metabolites after exercise, which was 
more evident in DMD than BMD patients [92-97].
The interest in imaging in DMD and BMD diminished for some years after these initial 
studies. The recent development of potential therapies for DMD prompted an increasing 
number of MR studies. Various MR techniques are thought eligible to identify changes 
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in the muscle that can be used as markers of disease progression. One of the most 
striking macroscopic changes in muscles of DMD and BMD patients is the increasing 
amount of fat replacement of muscle with progression of the disease. Consequently 
the main focus with regards to MRI in these patients has been on the assessment of the 
distribution of fatty changes, semi-quantitative and quantitative measurement of the 
fat and the relation of the remaining viable muscle with muscle function and strength 
[98-109]. Additionally, some studies have focused on the presence of oedema in the 
muscles and applied MRS to evaluate the lipid and energy metabolism [103, 108, 
110-115].
sCoPe oF the thesIs
At the start of this thesis there was little imaging data available on quantitative 
methods that could be used as outcome parameter in dystrophinopathy patients while 
several promising therapeutic approaches were being developed for these patients. 
Therefore, the aim of this thesis was to evaluate several MR methods that could serve 
as potential outcome parameters in the assessment of muscle pathology in DMD and 
BMD patients. In chapter 2 we compare a visual, semi-quantitative, scoring method 
to quantitatively score fat fractions in DMD patients and compare different models to 
account for the multiple peaks in the fat spectrum using the 3-point Dixon technique. 
In chapter 3 we use the 3-point Dixon technique to differentiate between contractile 
and non-contractile, fatty infiltrated, muscle in combination with quantitative strength 
measurements in DMD patients. In chapter 4 we explore the relation between the qual-
ity and quantity of dystrophin with the amount of fatty infiltration in the lower leg of 
BMD patients. In chapter 5 we focus on the muscle T2 relaxation times as indicator of 
oedema/inflammation in the muscle in DMD and BMD patients and healthy controls. 
Finally, in chapter 6 we use 31P MRS in BMD patients in combination with Dixon 
MRI to investigate metabolic changes in lower leg muscles of BMD patients with 



















































Comparison of Dixon and t1- 
weighted MR methods to assess 
the degree of fat infiltration in 
Duchenne muscular dystrophy 
patients
B.H. Wokke, C. Bos, M. Reijnierse, C.S. van Rijswijk, 
H. Eggers, A.Webb, J.J. Verschuuren, H.E. Kan





To compare different lipid multi-peak spectral models to the single peak model in 
Dixon based fat-water separation and to evaluate differences between visually scored 
MR images and quantitatively assessed fat fractions in muscle of Duchenne muscular 
dystrophy patients.
Materials and methods
T1-weighted and 3-point Dixon imaging of the upper and lower leg was performed 
in thirteen Duchenne patients and six healthy controls. Three-, four- and five peak 
lipid spectrum models were compared to a single peak model and to each other. T1-
weighted images were visually scored by two radiologists and quantitative fat fractions 
were obtained from Dixon images.
Results
Differences between the multiple-peak spectral models were minimal. The three-peak 
model was used for subsequent comparisons. Although there was high correlation 
between quantitative and visual scores, visual scores were consistently higher than 
quantitative values of the same muscles.
Conclusion
There are minor differences between the various lipid spectral models in terms of 
quantifying fat fraction in a large number of skeletal muscles in the legs of Duchenne 
patients and healthy controls. Quantitative 3-point Dixon MRI is more precise and 
reliable than visual radiological methods for evaluation of fat fractions for potential 
longitudinal follow-up or therapy evaluation of Duchenne patients.
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Muscle MRI is increasingly being used in the evaluation of disease severity in neuro-
muscular diseases such as Duchenne muscular dystrophy (DMD) [98, 99, 109, 116]. 
DMD is a progressive muscle disease affecting young males and results in a severely 
reduced life expectancy of ~30 years. Skeletal muscles of DMD patients show hy-
pertrophy, inflammation, progressive fatty infiltration and fibrosis. The level of fatty 
infiltration is considered to be a useful parameter to quantify the effect of new thera-
peutic interventions, and can potentially be measured accurately using non-invasive 
MRI protocols [77, 78, 117].
Chemical shift based water-fat separation methods such as the Dixon method use the 
phase difference between water and fat to separate these two components. As such, 
they can give a quantitative measure of the signal fraction of both water and fat. The 
first goal of our study was to compare the performance of different lipid spectrum mod-
els (three-, four- and five- peaks) to the single peak model of the lipid spectrum in fatty 
infiltrated muscles of DMD patients, using images acquired with a three-point Dixon 
method [98, 118-121]. In its most basic form, processing of the Dixon data models the 
fat signal as a single spectral peak, although the fat signal in fact contains multiple 
peaks from different saturated methyl and methylene protons, as well as unsaturated 
methyne groups. Previous studies have shown both in vitro and in liver, that modelling 
of the fat signals as multiple peaks significantly improves the fit and performs better in 
tissue with higher fat fractions [119, 122]. However, it is unknown how the multipeak 
spectral model behaves in much more spatially inhomogeneous tissues such as fatty 
infiltrated muscle.
There are various “semi-quantitative” visual-assessment scales available to describe 
the fatty infiltration in the muscle [101, 123-126]. However, although such scales 
are very quick to implement for the practicing radiologist, a recent study shows that 
semi-quantitative assessment of the fat fraction in muscles of patients with diabetes 
overestimates the fatty infiltration when compared to quantitative MRI methods [127]. 
Most patients in this previous study had relatively low levels of fatty infiltration 
and it is currently not known if this overestimation is still present if the muscle fat 
fraction is very high, as is often observed in DMD patients. Additionally, in patients 
with increased levels of fatty infiltration in the muscles, visual assessment of the fatty 
infiltration, especially in intermediate fat ranges, is likely to be less sensitive in detect-
ing small changes [102]. Therefore, these methods could be less suitable for longitu-
dinal follow up or therapy assessment. The second aim of our study was to compare 
“semi-quantitative” fat fractions obtained with an accepted neurological visual scoring 
method with those obtained using the quantitative MRI method outlined in the first part 





In total thirteen DMD patients (mean age 10.8 ± 2.0 years; range 8-14 years) and six 
healthy controls (mean age 11 ± 0.9 years; range 10-12 years) participated in this 
study. For the reconstruction with a different number of peaks, raw data are needed. 
As they were not present for all subjects data sets of nine patients (mean age 10.6 
years ± 1.9; range 8-14 years) and six healthy controls (mean age 11 years ± 0.9; range 
10-12 years) were used for the comparison of single- versus multipeak modelling. 
For the comparison of the semi-quantitative and quantitative analysis the images of 
ten patients (mean age 10.3 ± 1.9 years; range 8-13 years) were analysed using the 
three-peak model [122].
Patients were recruited from the Dutch dystrophinopathy database. Diagnosis of DMD 
was confirmed by DNA testing or muscle biopsy showing absence of dystrophin. Pa-
tients had no history of illness other than DMD. Healthy subjects were recruited from 
local schools. The local medical ethics committee approved the study and all subjects 
or their legal representative gave written informed consent.
MRI
MR images were acquired on a 3T scanner (Achieva, Philips Healthcare, Best, The 
Netherlands) from the left upper and lower leg using a 14-cm diameter two-element 
receive coil and body coil excitation. The receive coils were positioned on the anterior 
and posterior side of the leg; directly below the patella for lower leg imaging and directly 
above the patella for upper leg imaging. The left leg was imaged since this allowed opti-
mal positioning of the coil in all patients, even those with some contractures, with respect 
to the patient table and the coil. The scanning protocol consisted of a T1-weighted spin 
echo (SE) sequence (25 five mm slices, 0.5 mm gap, repetition time (TR) 600ms, echo 
time (TE) 16ms) and a 3-point gradient echo Dixon sequence of the same region of 
interest (25 five mm slices identical to the T1- weighted slices, 0.5 mm gap, TR 400 ms, 
first TE 4.41 ms, echo spacing 0.71 ms, flip angle 8°). The TR of 400 ms and low flip 
angle of 8° were chosen to produce minimal T1 weighting. The total scanning protocol, 
including positioning of the patients, was performed in 20 minutes.
Quantitative analysis
The 3-point Dixon images were reconstructed with the lipid spectrum modelled as a 
single peak or multiple peaks using three different lipid spectrum models. The first 
model was a three peak model with frequencies fp=[94, -318, -420] Hz and ampli-
tudes Ap=[0.08, 0.15, 0.78] and was based on the model proposed by Yu et al. [122]. 
The four peak model resolves the peak from the terminal CH3 group from the large 
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aliphatic peak with fp=[94, -318, -418, -470] Hz and Ap=[0.08, 0.15, 0.72, 0.04], and it 
was obtained by a weighted average of the signals at -300 and -325 Hz from the five 
peak model. Finally, a five peak model with fp=[94, -300, -325, -418, -470] Hz and 
Ap=[0.08, 0.05, 0.1, 0.72, 0.04] was implemented [128]. The five peak model separates 
the α-methylene protons of the COO and C=C bonds into two separate signals. To 
obtain fat fractions per muscle, regions of interest (ROIs) were manually drawn using 
Medical Image Processing, Analysis and Visualization software package (www.mipav.
cit.nih.gov) on co-registered T1 images on every other slice provided that the muscle 
was clearly identifiable. The fat fraction was modelled as SIfat/(SIfat+cSIwater), with SI 
representing the signal intensity and the factor c (1.41) correcting for differences in the 
proton densities of water and fat, as well as the differences in the T2 values of water 
(38 ms) and fat (150 ms). In order to obtain realistic proton density and T2 values, 
these were measured in one healthy control. T2 values were measured by using a single 
slice multi-echo experiment. The proton densities were estimated using a single slice 
spin echo sequence with TR/TE 5000 ms/6 ms, and then back-calculating the signal 
intensity for a virtual echo time of 0 ms using the T2 values measured previously.
Visual scoring
T1-weighted images of the left upper and lower leg of ten patients (mean age 10.3 
years ± 1.9; range 8-13) were scored in consensus by two experienced musculoskeletal 
radiologists. For the scoring the available slices within the entire field-of-view, which 
was identical to the Dixon images, were used. A visual 4-point scale classified muscle 
as: 1-normal muscle, 2-mild changes of less than 30% estimated fatty infiltration, 
3-moderate changes of 30-60% estimated fatty infiltration, and 4-severe changes of 
more than an estimated 60% showing an increased signal intensity [123]. The following 
muscles were scored in the upper leg: rectus femoris, vastus lateralis, vastus interme-
dius, vastus medialis, short head of the biceps femoris, long head of the biceps femoris, 
semitendinosus, semimembranosus, adductor longus, adductor magnus, gracilis and 
sartorius, and in the lower leg: medial and lateral head of the gastrocnemius, soleus, 
flexor digitorum longus, flexor hallucis longus, posterior tibialis, extensor hallucis 
longus, peroneus, anterior tibialis and extensor digitorum longus.
statistical analysis
The SPSS statistical package Version 17.0 for Windows (SPSS Inc., Chicago, IL) was 
used for all analyses. A box plot was used to visualize differences between the visual 
and quantitative scoring methods and a Spearman correlation was used to compare the 
two methods. To evaluate differences between the different multipeak models a Bland-
Altman plot was used. Statistical significance was set at p<0.05. Values are shown as 




single versus multipeak analysis
Figure 1 shows the comparison of the three different multipeak models to the single 
peak model. In the range of 0-70% fatty infiltration the multipeak models consistently 
show higher fat fractions than the single peak model. The difference between the 
models is most prominent in the range of 20-50% fatty infiltration and negligible in the 
very high ranges. Subtracted images of the single peak and the three peak model (Fig-
ure 2a.) show a clear difference between these two models, which is much less evident 
between the three- and the five peak model (Figure 2b), showing predominantly noise. 
Figure 1. Single peak model versus three peak, four peak and five peak spectral model. 
The four peak model deviates most from the single peak model. For all three models the differences are 
most apparent in the mid-range of the fat fraction.
Figure 2. Subtracted images of the different spectral peak models. 
The three peak minus the single peak model (a) shows a clear difference between the fat fractions of the 
two models. The five peak minus the three peak model (b) shows much smaller differences and mainly 
noise.
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Figure 3 shows the difference between the four and the five peak model as compared 
to the three peak model. Both the four and the five peak model show very slightly 
higher fat fractions than the three peak model, with the four peak model showing less 
variability in the data. Nevertheless, the differences between the models were so small 
that in the subsequent comparisons the three peak model was used.
Figure 3. Bland-Altman plot showing the differences between the four and five peak model compared 
to the three peak model for the average fat fraction. 
The four peak model shows less variation in the values which would make the model more precise than 
the five peak model.
Figure 4. Upper leg of DMD patient showing the T1 weighted image (a) and a color representation of 
the fat fraction in the Dixon image (b).
Chapter 2
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Visual scoring and quantitative analysis
In ten patients fat fractions from a total of 201 muscles were scored on the 4-point 
scale. Of these, 17 (8.5%) were scored as normal, 62 (30.8%) as mildly affected, 34 
(16.9%) as moderately affected and 88 (43.8%) as severely affected. The same muscles 
were analysed using the data from the 3-point Dixon scans (Figure 4).
There was a significant correlation between the two scoring methods, Spearman r=0.89, 
p<0.0001. Figure 5 shows how the quantitative Dixon values relate to the visual scores. 
Two main differences were noted. First, the visually scored fat fractions were higher than 
their quantitative equivalents, except for normal appearing muscle (Figures 5 and 6). 
Second, the variation in the values of the quantitative fat fraction scores was higher with 
increasing visually scored values. The variation was most evident in the visually scored 
group of severely affected muscles, defined as more than 60% fatty infiltration. Quantita-
tive fat values in this group ranged from a minimum of 16% up to a maximum of 86%.
Overall, in healthy controls the mean quantitative fat fraction was 5.3 ± 0.98% ranging 
from 3 to 10%. The mean quantitative fat fraction in the patients was 29.7 ± 13.2% 
ranging from 5 to 86%.
DIsCussIon
The first aim of our study was to evaluate the performance of the multipeak models of 
the lipid spectrum in chemical shift-based water-fat separation over the entire range 
of healthy to severely affected muscles. Several previous in vitro and in vivo liver 
studies have shown that accounting for multiple peaks (up to six) of the lipid spectrum 
Figure 5. Visually scored versus quantitative fat fractions. 
With visually scored fat scores as 1: normal appearing muscle, 2: mildly affected muscle (<30%), 3: 
moderately affected muscle (30-60%) and 4: severely affected muscle (>60%). Especially in the third 
and the fourth group of the semi-quantitative values there is large variation of the quantitative values.
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results in a more accurate measurement of the fat fraction. In this paper we have shown 
that in muscle of healthy controls and DMD patients with varying disease severity 
multipeak models shows consistently higher fat fractions in the range of 0-70% fatty 
infiltration. Compared to the multipeak models, single peak modeling underestimates 
the fat fraction in the range of these values, and this underestimation is a non-linear 
function of fat fraction. Overall there were very minor differences in the estimate of 
fat fraction using a three-, four- or five peak model. The difference between these 
results, and those acquired in phantoms and in liver, could be that the lipid spectrum 
depends significantly upon muscle fiber orientation. This results in a shift of the lipid 
peaks and consequently increases the sensitivity of the model to the specific frequency 
of the spectral peaks [129], whereas there is no such variation in either homogenous 
phantoms or liver tissue.
Accurate fat quantification in chemical shift-based water-fat separation can also be 
influenced by other factors such as the difference in T1 values between fat and water 
(which itself is dependent upon the fat/water fraction in a particular voxel) if the im-
ages are T1-weighted [122, 129-131]. By choosing a low flip angle and a long TR in 
this study T1 effects were minimized [130]. Additionally, as mentioned above, the 
lipid spectrum depends significantly upon muscle fiber orientation and this could also 
affect its quantification. However, as in multi echo acquisitions with a low number of 
echoes and a short range of echo times the influence of these shifts on the resulting 
signal is relatively small [129].
Figure 6. T1 weighted image of upper leg of DMD patient comparing visually scored and quantitative 
values. 
The vastus lateralis visual score was 4 (severely affected) with a quantitative fat fraction of 33%. The ad-
ductor magnus (AM) visual score 4 with fat fraction 47%, sartorius (S) visual score 2 (mild changes) and 
fat fraction 10% and for the semimembranosus (SM) the visual score was 4 with a fat fraction of 24%.
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The second aim of our study was to compare a radiological visual scoring method of the 
fat fraction with quantitative MRI values in both healthy and fatty infiltrated muscles. 
The mean quantitative fat fraction in our healthy volunteers was in agreement with a 
recent study [132]. In muscle of healthy controls and DMD patients with relatively low 
fat fractions, the visual scores were highly correlated with the quantitatively obtained fat 
fractions. However, the visual scores for the fat fractions in the muscle were generally 
higher than their corresponding quantitative values. This finding implies that the visual 
scoring measurements overestimate the fat fraction in affected muscles. Alizai et al. 
showed a similar finding in the muscle of diabetes patients: in this study most patients 
were only relatively mildly affected [127]. Our data shows large variation between the 
visually scored and quantitative values, specifically in the severely affected muscles. 
The large variability of the visually-scored method illustrates that these methods are 
less sensitive for the recognition of subtle changes, as could be present in longitudinal 
follow up of DMD patients or in therapy evaluation [133]. The overestimation and 
possibly also the variation of the fat fraction with the visually scored methods could 
partly be explained by the difficulty in visually differentiating between a moderate 
and severely fatty infiltrated voxel, which has also been suggested by Alizai [127]. 
Secondly it might be difficult to consistently estimate the amount of muscle left in a 
diffusely fatty infiltrated muscle as frequently observed in the DMD patients. In the 
radiological literature the Goutallier classification is commonly used, (normal muscle, 
fatty streaks, less fat than muscle, as much fat as muscle and more fat than muscle) 
[125]. This might be easier to use in scoring fatty infiltration of muscle by the human 
eye. However, the largest differences are seen in the most severely fatty infiltrated 
muscles. Both the overestimation of the fat fraction and the large variability in visually 
scored DMD muscle can influence the assessment of possible changes in the muscles 
in longitudinal follow up of or in the evaluation of therapy effects. Therefore, in these 
situations quantitative evaluation of the fat fraction seems more precise and reliable 
than visual radiological methods.
There were also some limitations to our study; most importantly no validation of the 
data with histology was made. A previous study has shown that values obtained with 
chemical shift-based water-fat separation methods are generally in accordance with 
data obtained from muscle biopsy [134]. The multipeak approach has previously been 
validated with in vitro measurements and MR spectroscopy and we therefore assume 
that any of our multipeak models are more representative of the actual fat fraction than 
a single peak model [119, 122, 135]. Another limitation of our study could be that a 
relatively low number of subjects were included. However, as a total of 201 different 
muscles were scored, the number of data points used for the comparison was very high.
 In conclusion our results show that visually scored assessment of the fat fraction gen-
erally correlates with quantitative values, but overestimates the fat fraction and shows 
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higher variability. Quantitative MRI methods such as chemical shift-based water-fat 
separation produce a more accurate estimation of the fat fraction, especially in the 
more severely affected muscle. Correcting for the multiple peaks of the lipid spectrum 
contributes to obtaining more precise fat fractions. These findings further stress the 
importance of quantitative evaluation of the fat fraction to accurately demonstrate 


















































Quantitative MRI and strength 
measurements in the assessment 
of muscle quality in Duchenne 
muscular dystrophy
B.H. Wokke, J.C. van den Bergen, M.J. Versluis, E.H. Niks, 
J.Milles, A.G. Webb, E.W. van Zwet, A. Aartsma-Rus, 
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The purpose of this study was to assess leg muscle quality and give a detailed de-
scription of leg muscle involvement in Duchenne muscular dystrophy patients using 
quantitative MRI and strength measurements. Fatty infiltration as well as the total 
and contractile (not fatty infiltrated) cross sectional areas of various leg muscles were 
determined in 16 Duchenne patients and 11 controls (aged 8 to 15). To determine 
specific muscle strength, four leg muscle groups (quadriceps femoris, hamstrings, an-
terior tibialis and triceps surae) were measured and related to the amount of contractile 
tissue. In patients, the quadriceps femoris showed a decreased total and contractile 
cross sectional area, attributable to muscle atrophy. The total, but not the contractile, 
cross sectional area of the triceps surae was increased in patients, corresponding to hy-
pertrophy. Specific strength decreased in all four muscle groups of Duchenne patients, 
indicating reduced muscle quality. This suggests that muscle hypertrophy and fatty 
infiltration are two distinct pathological processes, differing between muscle groups. 
Additionally, the quality of remaining muscle fibers is severely reduced in the legs of 
Duchenne patients. The combination of quantitative MRI and quantitative muscle test-
ing could be a valuable outcome parameter in longitudinal studies and in the follow-up 
of therapeutic effects.
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Duchenne muscular dystrophy (DMD) is an X-linked muscle disease affecting ap-
proximately 1 in 3500 male newborns. Patients develop progressive muscle weakness 
and become wheelchair-dependent around the age of twelve. They have a severely 
reduced life expectancy due to cardiac and respiratory problems [136]. DMD is caused 
by the absence of functional dystrophin, due to mutations in the DMD gene. This 
causes inflammation, muscle fiber necrosis and replacement of fibers by connective 
and fatty tissue [10, 38, 54].
Several promising therapies for DMD are currently being tested in clinical trials [77, 
137-139]. Histological analysis of a muscle biopsy is an important outcome parameter 
for the evaluation of therapeutic effects. However, this procedure is invasive and pro-
vides only local information on a single muscle, whereas it is known that muscles are 
not affected equally and a distribution of pathological changes can occur even within 
a single muscle.
Quantitative non-invasive magnetic resonance imaging (MRI) of muscle is increasingly 
being used to assess disease-related parameters in DMD patients [98, 99, 103-107, 
109, 111, 116, 140]. A commonly used parameter is fatty infiltration, which has been 
shown to correlate with age and muscle function in the upper leg [91, 98, 101, 106, 
140]. With MRI, fatty infiltration can be quantified using several approaches, including 
methods based on signal intensity differences, which rely on thresholding bright fat 
pixels and lower intensity water pixels, chemical shift based approaches which rely on 
the difference in chemical shift between water and fat, and T2 maps which rely on the 
difference in T2 relaxation time between water and fat. Signal intensity approaches can 
be biased by partial volume effects (i.e. a voxel seldom solely consist of either fat or 
water) resulting in an inaccurate assessment of the fat fraction and T2 based methods 
can be significantly influenced by B1 inhomogeneities. In contrast, chemical shift 
based fat-water separation methods such as the 3-point Dixon technique are less biased 
by partial volume effects compared to thresholding approaches and are less influenced 
by B0 and B1 magnetic field inhomogeneities. Additionally, fat fractions obtained by 
this method have been shown to correlate well with histology and magnetic resonance 
spectroscopy (MRS) [105, 134].
The functional consequences of fatty infiltration i.e. a decrease in the amount of 
contractile tissue have recently been described for the quadriceps femoris, but not for 
other muscle groups in the upper and lower leg [140]. However, it is known that in 
DMD patients different muscles become affected at different stages of the disease and 
hence some muscles remain preserved longer than others [91, 113, 141]. In the lower 
leg, hypertrophy of the calf muscles has frequently been noted, but its effect on muscle 
function and the relation with fatty infiltration and age has not been described in detail.
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In order to address the issues of limited volumetric coverage of only a few muscle 
groups from previous publications, here we studied fatty infiltration and muscle vol-
ume in four different muscle groups in the upper and lower leg of DMD patients using 
quantitative MRI with the 3-point Dixon technique [118, 142]. An additional aim of 
our study was to obtain a measure for muscle quality for each of these muscle groups 
by comparing the MR parameters to muscle strength. A non-invasive description of 
muscle quality would be very valuable to increase our knowledge of the pathophysiol-




Sixteen DMD patients (mean age 11.4 ± 2.2 years, range 8-14 years) and eleven healthy 
male controls (mean age 10.7± 2.1 years, range 8-15 years) participated in the study. 
Patients were recruited from the Dutch dystrophinopathy database. Diagnosis had been 
confirmed by DNA or muscle biopsy in all patients. Healthy subjects in the same age 
range were recruited from local schools and sports clubs. Exclusion criteria were the 
presence of contra-indications for the MRI and inability to lie supine for 30 minutes. 
The local medical ethics committee approved the study. Written informed consent was 
obtained from subjects and parents before inclusion.
MRI
MR images from the left upper and lower leg were acquired on a 3T scanner (Achieva, 
Philips Healthcare, Best, The Netherlands) using one 14-cm two-element receive coil 
with body coil excitation for both the upper and lower leg. The receive coil elements 
were positioned on the anterior and posterior side of the leg; directly below the patella 
for lower leg imaging and directly above the patella for upper leg imaging. The scan-
ning protocol consisted of a survey scan for positioning, a T1-weighted turbo spin echo 
(TSE) sequence (twenty-five slices of five mm thickness, 0.5 mm gap, repetition time 
(TR) 600 ms, echo time (TE) 16ms, field of view (FOV) 180x180x137 mm, voxel size 
0.9x0.9 mm, TSE factor 5) and a 3-point gradient echo Dixon sequence (twenty-five 
slices of five mm thickness, 0.5 mm gap, TR 400 ms, first TE 4.41 ms, echo spacing 
0.76 ms, flip angle 8°, FOV 180x180x137 mm, voxel size 0.6x0.6 mm) of the upper 
and lower leg. The T1 and Dixon scans were planned using the survey scan, so that the 
central slice would be at the part of the lower leg with the largest diameter, and cover 
a significant part of quadriceps in the upper leg. The total scanning protocol, including 
positioning of the patients, could be completed in 25 minutes.
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The 3-point Dixon images were reconstructed with multipeak correction as proposed 
by Yu et al. with frequencies fp=[94, -318, -420] Hz and amplitudes Ap=[0.08, 0.15, 
0.78], to account for the multiple peaks of the fat spectrum [122, 143].
Regions of interest (ROIs) were drawn manually using Medical Image Processing, 
Analysis and Visualization software package (http://mipav.cit.nih.gov) on T1-weight-
ed images in the following muscles of the upper leg: rectus femoris, vastus lateralis, 
vastus intermedius, vastus medialis, short head of the biceps femoris, long head of 
the biceps femoris, semitendinosus, semimembranosus, adductor longus, adductor 
magnus, gracilis and sartorius. In the lower leg the muscle groups were: medial head of 
the gastrocnemius, lateral head of the gastrocnemius, soleus, flexor digitorum longus, 
flexor hallucis longus, posterior tibialis, extensor hallucis longus, peroneus, anterior 
tibialis and extensor digitorum longus. ROIs were drawn on every other slice, provided 
that the muscles were clearly identifiable in the slices.
The average fat fraction per muscle was computed using the co-registered contours 
from the T1w images on the Dixon images and calculated by averaging all pixels 
assigned to that muscle. The fat fraction was modelled as SIfat/(SIfat+cSIwater), with 
SI = signal intensity and the factor c (1.41) correcting for differences in proton density 
and T2 relaxation times between water and fat. We used T2 instead of T2* in our 
correction as we used a three echo method and therefore could not reliably determine 
T2* [144]. Proton density and T2 relaxation times of water and fat were measured in 
the muscle and subcutaneous fat of one healthy volunteer using the assumption that 
T2 values of subcutaneous fat and highly fat infiltrated muscle are similar [143, 145].
To assess total cross sectional area (CSA) in the upper leg the most proximal slice in 
which the short-head of the biceps femoris could be identified was used, as described 
by Akima et al. [140]. For the lower leg the total CSA was determined separately 
for the anterior tibialis and the triceps surae in the slice or slices with the largest 
CSA of the muscles on the axial images [100]. For the contributing muscles for knee 
extension (quadriceps femoris; i.e. rectus femoris, vastus lateralis, vastus medialis, 
vastus intermedius), knee flexion (hamstrings; i.e. biceps femoris long and short head, 
semimembranosus, semitendinosus), ankle dorsiflexion (anterior tibialis) and ankle 
plantar flexion (triceps surae; i.e. gastrocnemius medial and lateral head, soleus), the 
relation between the contractile CSA and strength was assessed. Contractile CSA was 
calculated from the mean fat fraction and the total cross sectional area (i.e. the cross 
sectional area including fat and muscle tissue) of these muscles (contractile CSA= 
total CSA x (100-mean fat percentage in entire muscle volume)/100). As a measure for 





A quantitative muscle assessment (QMA) system (www.qmasystem.com) was used 
to assess knee flexion, knee extension, and ankle plantar- and dorsiflexion in both 
patients and controls. Maximal voluntary isometric contraction was obtained using 
a fixed myometer. For knee flexion and knee extension patients were tested in sitting 
position, with hip and knee at 90˚ flexion with the strap attached around their ankle. 
Ankle plantar- and dorsiflexion were assessed in a supine position with the hip at 
full extension; heel slightly raised with the calf on a cushion and strap around the 
metatarsals [146]. The highest value of three consecutive measurements was used as 
the maximum strength. If a measurement differed more than 10% from previous mea-
surements, it was discarded and an extra measurement was performed. Measurements 
were performed after the MRI.
statistical analysis
To assess differences between patients and controls in total CSA, contractile CSA, 
peak muscle strength and specific strength (strength per mm2 of contractile tissue), 
general linear models were used with Duchenne status as a fixed factor and normalized 
age (i.e. age – average) as a covariate. Bonferoni-Holms correction was used to correct 
for the multiple comparisons in this analysis. A student’s t-test was used to test for 
differences in patients’ age, height and weight. Pearson correlation analysis was per-
formed to assess the relation between peak muscle strength (kg) and contractile CSA 
(mm2). The SPSS statistical package Version 20.0 for Windows (SPSS Inc., Chicago, 
IL) was used for the analysis. The level of statistical significance was set at p<0.05.
Results
Patient characteristics are shown in Table 1. All healthy controls completed the MRI 
protocol, but in two DMD patients only the lower leg was scanned. One patient was 
unable to lie on his back for more than 15 minutes and one patient wore braces, which 
prevented accurate positioning in the scanner for upper leg scanning. There were 
no significant differences in age, weight and height between patients and controls 
(Table 1). Twelve patients were on corticosteroids during the study (one patient used 
deflazacort, eleven used prednisone). Of the four patients not on steroids, two 13-year 
old boys had been on steroids for several years up to one year prior to the study. Two 
DMD boys (8 and 13 yrs) had never used corticosteroids.
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To evaluate the disease severity and the pattern of muscle involvement fat fractions 
were calculated for all muscles. The mean fat fraction in patients in the leg muscles 
was 28.8 ± 22.8% (range 2-86%). In controls the value was 5.3 ± 1.5% (range 3-10%).
Compared to controls all patients showed increased fat fractions (i.e. higher than the 
mean plus two times the SD of the control values of that muscle) in at least one muscle 
of the upper leg and lower leg (Figures 1 and 2). The flexor digitorum longus and ex-
tensor hallucis longus could not be identified in all patients and/or in all slices because 
of a limited field-of-view in the cranial-caudal direction.
table 1. Patient demographics.
Patients Controls P value
Age (years) 11.4 ± 2.2 10.7 ± 2.0 0.40
Height (m) 1.48 ± 0.1 1.54 ± 0.1 0.38
Weight (kg) 48.6 ± 12.5 41.9 ± 12.1 0.17
Corticosteroid use 12/16 0/11
Mobility
- Fully ambulant 7/16 11/11  
- Wheelchair user 2/16 0/11  
- Wheelchair dependent 7/16 0/11  
a. 
f. e. d. 
c. b. 
Figure 1. T1 weighted and Dixon MR image of upper and lower leg.




total and contractile cross sectional area
The total CSA of the quadriceps femoris muscles was smaller in patients than in 
healthy controls (Table 2). For the hamstrings and anterior tibialis there were no 
significant differences in the total CSA between the groups. In the triceps surae the 
total CSA in patients was significantly larger than in healthy controls. In controls total 
CSA increased significantly with age in all muscle groups (p<0.03) (Figure 3a-d). In 
patients, however, no significant correlation between total CSA with age was found.
The contractile CSA in the quadriceps femoris and hamstrings was smaller in patients 
than in healthy controls (Table 2). For the other two muscle groups there were no 
significant differences in contractile CSA between patients and controls. In healthy 
controls contractile CSA increased significantly with age (p<0.02), but no such rela-
tion was observed in the patients.
Figure 2. Box and whisker plot of the average fat fraction per muscle in upper and lower leg of DMD 
patients and healthy controls.
Fat fractions shown for all patients in all muscles of the upper leg (white) and lower leg (grey) and for 
all healthy controls (black). The upper leg is more affected compared to the lower leg muscles. Values 
shown as median ± maximum and minimum and are ordered by the mean fat fraction (+).
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Peak muscle strength was significantly lower in patients than in healthy controls for 
all four muscle groups (Table 2). In controls, muscle strength increased significantly 
with age in all muscle groups (p<0.001). In patients only the strength of the anterior 
tibialis and the triceps surae increased with age (p=0.035 and p=0.003 respectively). 
Significant positive correlations between peak muscle strength and contractile CSA 
were found for all muscle groups in controls. In patients there was a significant cor-
relation in the quadriceps, hamstrings and anterior tibialis, but no significant relation 
in the triceps surae (Figure 4). To assess muscle quality, we compared the specific 
strength between patients and controls. In DMD patients this was significantly lower in 
all muscle groups compared to controls (Table 2). In controls specific strength did not 
increase with age, while in patients an increase of specific strength with age was seen 
in the triceps surae (p< 0.001) and the tibialis anterior (p= 0.03).
table 2. Muscle characteristics in patients and controls.
Patients Controls P value
Total CSA (mm2) Quadriceps femoris 2889 ± 974 4203 ± 1203 <0.001
Hamstrings 2071 ± 580 1753 ± 630 0.33
Anterior tibialis 475 ± 115 439 ± 142 0.87
Triceps surae 4671 ± 1373 3081 ± 960 0.016
Contractile CSA (mm2) Quadriceps femoris 1527 ± 509 3955 ± 1098 <0.001
Hamstrings 1255 ± 531 1669 ± 591 0.02
Anterior tibialis 377 ± 114 421 ± 135 0. 22
Triceps surae 3454 ± 1159 2875 ± 953 0.27
Peak muscle strength (kg) Quadriceps femoris 5.9 ± 3 27.0 ± 10 <0.001
Hamstrings 6.8 ± 3 19.4 ± 7 <0.001
Anterior tibialis 7.4 ± 4 18.5 ± 7 <0.001
Triceps surae 12.0 ± 8 25.7 ± 8 <0.001
Specific strength (kg/mm2) Quadriceps femoris 3.9 ± 1.6 6.7 ± 0.8 <0.001
Hamstrings 5.8 ± 2.4 11.6 ± 1.8 <0.001
Anterior tibialis 18.7 ± 9.2 43.4 ± 7.9 <0.001
Triceps surae 3.6 ± 2.1 9.1 ± 1.3 <0.001
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Figure 3. Plots of total contractile area and fat percentage.
In patients no significant increase in total cross sectional area (CSA) was found with age, whereas in 
controls a significant relation was found in three muscle groups (a-d). In all four muscles in patients the 
fat percentage increases with age, but it starts later the lower leg compared to the upper leg (e-h).
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Our data show that the absence of dystrophin elicits significantly different responses in 
the four main muscle groups of the leg in terms of muscle volume and fatty infiltration. 
The quadriceps and triceps surae represent two ends of the spectrum, while the ham-
strings and anterior tibialis have an intermediate phenotype. In addition, the specific 
strength of the muscles was significantly lower for all four muscle groups compared 
with healthy controls confirming a reduction in muscle quality.
The most severely fatty infiltrated muscle in patients was the adductor magnus, fol-
lowed by the individual muscles of the quadriceps femoris and the biceps femoris 
longus, which is in accordance with previous studies [106, 109, 113, 141]. Overall, 
the lower leg was affected later in the disease, with the lateral and medial head of the 
gastrocnemius and the peroneus being most severely affected [111].
In patients, the total CSA of the triceps surae was significantly larger compared to 
healthy controls, while the contractile CSA (i.e. the area of the muscle that consists of 
muscle tissue with no fat) was similar to controls. An increased total CSA was already 
present in our youngest patients but did not increase further with age, suggesting early 
Figure 4. Relation between peak muscle strength and contractile cross sectional area.
Correlation between contractile cross-sectional area (CSA) and peak muscle strength in patients and 
controls in four different muscle groups.
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hypertrophy. Clinical hypertrophy of the triceps surae is well known in DMD patients 
and has been reported at a very young age. Hypertrophic fibres have been observed in 
muscle biopsies of DMD patients from 4 years and older [147]. In contrast, both the 
total CSA and the contractile CSA of the quadriceps femoris were smaller compared 
to healthy controls. The reduction in total CSA was already present in the youngest 
patients and remained stable with age, suggesting relative atrophy at a young age, 
which is in accordance with a previous muscle biopsy study [147]. The hamstrings 
and tibialis anterior showed no significant differences in total CSA compared to 
healthy controls but also showed no increase with age. The tendency towards a larger 
total CSA at younger age there indicates hypertrophy in these muscle groups as well. 
Taken together, our results suggest that the quadriceps femoris shows no or a mild 
hypertrophic response in young patients, the triceps surae shows hypertrophy and the 
hamstrings and anterior tibialis show an intermediate response.
Interestingly, the extent of the hypertrophic response does not seem to predict the 
extent of the fatty infiltration. The quadriceps femoris showed no clear hypertrophy, 
but did have severe fatty infiltration, which can be interpreted as a hallmark of an early 
and severely dystrophic muscle. On the other hand, the hamstrings showed a mild 
hypertrophic response, but also showed severe fatty infiltration [106]. In the lower 
leg, the triceps surae showed the greatest degree of hypertrophy, but the amount of 
fatty infiltration was similar to the tibialis anterior muscle, which only had a moderate 
hypertrophic response. Thus, the onset and progression of changes in muscle volume 
and fatty infiltration appear to be two distinct, independent pathological processes that 
differ in rate of progression between muscle groups.
In controls, muscle strength increased with age and with the amount of contractile 
tissue. The cross-sectional data from our patients showed no significant increase in 
muscle strength with age in the upper legs, but there was an increase in the lower 
legs. Additionally, DMD patients showed an overall reduction in the specific muscle 
strength. The availability of both quantitative MRI data and quantitative muscle 
strength measurements allowed us to calculate this parameter, which is an indication 
of the strength per muscle fiber, excluding the fatty infiltrated part of the muscle. 
The significantly lower specific strength in patients compared to controls for all four 
muscle groups indicates an overall reduction in muscle quality. This could be due to 
several factors, including limited capacity of the diseased muscle fibers to contract, re-
duced efficacy of force transduction to the connective tissue and tendons and increased 
muscle stiffness due to increased levels of fibrosis or as a result of disorganization 
and inefficient alignment of muscle fibers [148]. A similar observation has been made 
both in the quadriceps muscle of DMD patients and in mdx mice [140, 149]. In these 
mice isometric forces produced by soleus muscles from young mice were weaker than 
in wild type mice, when force was normalized for cross-sectional area. Surprisingly, 
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there appeared to be an increase in both strength and specific strength in the lower leg 
muscle groups with age in patients, while this increase was absent in controls. This 
could suggest that in patients, there is a selection of high quality muscle fibers, which 
might also have the ability to increase their capacity to generate force.
The current study has some limitations. The percentage of fatty infiltration (Figure 3) 
was relatively low in the 14 year old patients in our study compared to the other pa-
tients. This finding emphasizes that in DMD patients there is variability between how 
severely patients are affected. Nevertheless, these patients also show lower specific 
strength of the remaining muscle tissue compared to healthy controls, indicating that 
despite the relatively high amount of contractile tissue, there is a reduction in muscle 
quality in all muscle groups. Although we obtained a good match with healthy controls 
regarding age and height, a limitation of our study was the absence of longitudinal 
data. We compensated for this by analysing our data with age as a covariate, but true 
longitudinal data where muscle MRI and strength tests are combined might prove very 
fruitful in analysing the differences between dystrophic muscles [106]. We determined 
contractile CSA using the largest total CSA and the mean fat fraction for each muscle 
group. In DMD muscle, significant amounts of fat infiltration are present, and this 
fat will likely contribute only minimally to the force of that muscle. Fatty infiltration 
could be distributed inhomogenously across the muscle of DMD patients, and it is 
unclear how this could affect the muscle strength. As the whole muscle contributes 
to delivering force, taking into account only the fat percentage of one slice could bias 
the results. Therefore, we felt that using the mean fat fraction of a number of slices 
instead of the fat fraction from the slice used for determination of maximal CSA would 
provide a more realistic value of the contractile abilities of the muscle. Finally, we did 
not incorporate fitting of the T2* decay into our model of fat quantification, which 
could have led to a slight overestimation of the fat levels in our study.
In summary, progressive fatty infiltration is seen with a decrease in total volume in 
some muscles, but with muscle hypertrophy in others, which suggests that these are 
two distinct pathological processes, which differ over time between muscle groups. 
Quantitative MRI enabled us to calculate the fatty infiltration and thus contractile 
cross-sectional area, and this showed a reduction in muscle quality in DMD patients. 
This could yield valuable insight in the pathophysiology of dystrophic muscle and 
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Becker muscular dystrophy (BMD) is characterized by broad clinical variability. On-
going studies exploring dystrophin restoration in Duchenne muscular dystrophy ask 
for better understanding of the relation between dystrophin levels and disease severity. 
We studied this relation in BMD patients with varying mutations, including a large 
subset with an exon 45-47 deletion.
Methods
Dystrophin was quantified by Western blot analyses in a fresh muscle biopsy of the an-
terior tibial muscle. Disease severity was assessed using quantitative muscle strength 
measurements and functional disability scoring. MRI of the leg was performed in a 
subgroup to detect fatty infiltration.
Results
Thirty-three BMD patients participated. No linear relation was found between dystro-
phin levels (range 3-78%) and muscle strength or age at different disease milestones, 
in both the whole group and the subgroup of exon 45-47 deleted patients. However, 
patients with less than 10% dystrophin all showed a severe disease course. No rela-
tion was found between disease severity and age when analysing the whole group. 
By contrast, in the exon 45-47 deleted subgroup muscle strength and levels of fatty 
infiltration were significantly correlated with patients’ age.
Conclusion
Our study shows that dystrophin levels appear not to be a major determinant of disease 
severity in BMD, as long as it is above approximately 10%. A significant relation 
between age and disease course was only found in the exon 45-47 deletion subgroup. 
This suggests that at higher dystrophin levels the disease course depends more on the 
mutation site, than on the amount of the dystrophin protein produced.
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Becker and Duchenne muscular dystrophies (BMD and DMD) are caused by muta-
tions in the DMD gene encoding the dystrophin protein. Absence of dystrophin, as in 
DMD patients, or reduced levels of a semi-functionial dystrophin, as in BMD patients, 
leads to progressive muscle weakness due to continuous muscle fibre damage. While 
DMD is characterized by a relatively uniform disease course, disease progression in 
BMD is more variable [20, 150-153]. The mechanisms underlying this variability are 
not fully understood. Factors believed to be involved include the regenerative capacity 
of muscle tissue, inflammation as well as quantity and quality of the dystrophin protein 
[154-157]. Qualitatively, dystrophin has multiple functions that depend on the pres-
ence of functional domains within the protein, most importantly the N-terminal actin-
binding and the C-terminal beta-dystroglycan-binding domains. While the connecting 
‘central rod domain’ appears to be largely dispensable, the way in which remaining 
spectrin-like repeats are phased likely impacts dystrophin functionality [158]. An im-
portant role for dystrophin quantity has been suggested by previous reports, although 
there is still uncertainty about the nature of this relationship as both linear relations and 
a threshold effect have been suggested [150, 153-155, 159-164]. The interest in this 
possible relation increased with the development of the exon skipping technology in 
DMD [165, 166]. Clinical trials testing systemic delivery of antisense oligonucleotides 
(AONs) targeting exon 51 have shown restoration of dystrophin levels of up to 18% 
[77, 79].
In the present study we investigate the relation between dystrophin levels quantified 
from a freshly obtained muscle biopsy and disease severity in 33 BMD patients, in-
cluding 13 patients with an exon 45-47 deletion.
MAteRIAl AnD MethoDs
Patients
Adult BMD patients registered in the Dutch Dystrophinopathy Database were eligible 
to participate when complying with the following inclusion criteria: (1) in frame 
mutation in the DMD gene OR (2) any other mutation in the DMD gene AND a mild 
disease course, defined by age at wheelchair dependence after the age of 16 OR (3) 
no known mutation in the DMD gene AND reduced dystrophin staining in muscle 
biopsy. Patients using mechanical ventilation were excluded. During a one-day visit 
quantitative muscle testing of several muscle groups in upper and lower extremity and 
(optionally) a muscle biopsy of the anterior tibialis (TA) muscle was obtained from the 
study participants. The TA was chosen because it usually contains an adequate amount 
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of muscle tissue for dystrophin analysis in BMD patients with a wide range of disease 
severity, and since this muscle has also been used in several DMD exon skip trials [77, 
78]. Additionally, a quantitative MRI of the lower leg was obtained from the subgroup 
of participants with an exon 45 to 47 deletion who did not have a pacemaker or ICD, 
or severe contractures.
The local medical ethics committee approved the study and written informed consent 
was obtained from all subjects.
strength measurements
Quantitative muscle testing (QMT) was used to assess the maximal voluntary isomet-
ric contraction (MVIC). Measurements of the following muscle groups were obtained: 
elbow flexion and extension, handgrip and knee and hip flexion and extension. Ankle 
dorsiflexion was not included, as measurement of this muscle group has been shown 
to be unreliable [146]. Measurements were performed as described by Hogrel et al. 
[146]. Wheelchair dependent participants unable to make the transfer to the research 
bench were examined in their wheelchair. The mean of the bilaterally-tested muscle 
groups was calculated. To minimize the possible confounding effect of age and weight 
on the analyses, a z-score for muscle strength of the individual muscle groups was also 
calculated, taking these factors into account [146]. QMT was also performed in twenty 
male age-matched healthy volunteers.
Disease milestones
Disease milestones were used to compare disease severity between BMD patients, and 
thus to partially correct for the wide range of ages. A structured natural history was 
obtained from the 89 BMD patients with a genetically confirmed in-frame deletion in 
the Dutch Dystrophinopathy Database, including our participants. The data were used 
to determine the median ages as well as the 33rd and 66th percentile at which the follow-
ing disease milestones were reached: first motor symptoms, difficulty walking stairs, 
use of walking aids (braces, cane, walker or wheelchair) and wheelchair dependence.
Western blot analysis
The muscle biopsy from the TA was processed as previously described by Van Deu-
tekom et al. [78]. Protein lysates were generated from muscle biopsies and Western 
blotting were performed ac cording to previously described methods [78]. Monoclonal 
NCL-DYS1 (dilution 1:100, Novacastra, UK) or polyclonal ab15277 (dilution 1: 200 
Abcam, UK) were used to detect dystrophin. Rabbit polyclonal antibody to sarcomeric 
alpha-actinin (ACTN2) ab72592 (dilution 1: 500 Abcam, UK) was used as a loading 
control. Blots were visualized and quantified with the Odyssey system and software 
(Li-Cor, USA) as described previously [78]. Samples obtained from the TA and medial 
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and vastus lateralis muscles of five healthy males were used as reference samples. For 
each patient sample at least 2 technical replicates were performed.
Immunohistochemistry
Sections of 10 μm were cut from the TA biopsies using a Shandon Cryotome (Thermo 
Fisher Scientific Co., Pittsburgh, PA, USA). Sections were fixed for 1 min with ice-cold 
acetone. Goat polyclonal dystrophin diluted 1:50 (SC-7461, Santa Cruz Biotechnology, 
USA) was used to detect dystrophin. Alexa-fluor 488 donkey-anti goat IgG (A11055, 
Invitrogen, the Netherlands) diluted 1:1000 was used as a secondary antibody. Slides 
were analysed using a fluorescence microscope (DM RA2; Leica Microsystems Wet-
zlar, Germany), and digital images were taken using a CCD camera (CTR MIC; Leica 
Microsystems).
Muscle MRI
In BMD patients with an exon 45-47 deletion MR Images were acquired on a 3T scan-
ner (Achieva, Philips Healthcare, Best, The Netherlands) from the left lower leg using 
a 14-cm diameter two-element receive coil and body coil excitation. The scanning 
protocol consisted of a T1-weighted sequence (25 five mm slices, 0.5 mm gap, repeti-
tion time (TR) 600 ms, echo time (TE) 16 ms) and a 3-point Dixon sequence (25 five 
mm slices, 0.5 mm gap, TR 400 ms, first TE 4.41, echo spacing 0.76 ms, flip angle 8°) 
with multipeak analysis [122]. The mean fat fraction per muscle was calculated from 
regions of interest (ROIs) using Medical Image Processing, Analysis and Visualization 
(MIPAV) software. The medial and lateral head of the gastrocnemius, soleus, flexor 
digitorum longus, flexor hallucis longus, posterior tibialis, extensor hallucis longus, 
peroneus, tibialis anterior and extensor digitorum longus were analysed.
statistics
Pearson’s correlation test was used to analyse the relation between dystrophin expres-
sion, MVIC score and the mean fat fraction of the muscles. Dystrophin expression 
levels for the groups based on disease milestones were compared using an independent-
samples Student’s t-test. Differences between participants and non-participants as well 
as differences in disease milestones were analysed by Kaplan-Meier survival analysis, 
using the Log Rank test. SPSS version 16 for Windows (SPSS Inc., Chicago IL) was 





We approached 60 adult Becker patients to participate in the study of whom 33 
consented to participate (Table 1). Reasons not to participate included the physical 
burden, inability to attend due to work and travel distance to the Leiden University 
Medical Center. Participants did not differ significantly from non-participants in terms 
of age or age at reaching disease milestones (Table 2). Mean age of participants was 
40 years (± 13, range 19-66 years) versus 44 years (± 13, range 19-65 years) in the 
non-participating patients. 
The study population represented a wide clinical variety (Supplementary Table 1), 
ranging from a patient of 26 years who only noticed mild impairment while walking 
upstairs carrying heavy tools to a patient with a DMD-like phenotype (wheelchair-
dependence at the age of 10), but with an in frame deletion in the DMD gene and 
dystrophin expression as assessed by Western blot (see below).
table 1. Included BMD participants
DMD phenotype  
(loss of ambulation  
<12 years)
Intermediate 
phenotype (loss of 
ambulation  
13-16 years)
BMD phenotype  
(loss of ambulation  
>16 years)
In frame deletion 1 - 29
Out of frame deletion or point 
mutation
- - 2
Unknown mutation, reduced 
dystrophin staining
- - 1






Events Estimated mean Events Estimated mean
Age 40 (± 13) 44 (± 13) 0.27
First symptoms 31 12 (± 1.6) 26 11 (± 2.1) 0·41
Walking stairs 26 30 (± 3.0) 25 24 (± 2.7) 0.16
Walking aid 19 41 (± 3.6) 20 36 (± 3.4) 0.49
Wheelchair dependence 8 54 (± 3.2) 11 49 (± 3.4) 0.33
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Fresh muscle biopsies were obtained from 27 patients. Six patients refused a biopsy be-
cause of previous negative experiences. Dystrophin expression as assessed by Western 
blot (Figure 1 and Supplementary Figure 1) ranged from 4% to 71% of normal human 
skeletal muscle as detected by the rod-domain antibody (NCL-DYS1) and from 3% 
to 78% using the C-terminus antibody (AB15277). The mutation of one patient (exon 
29;c.3940C>T,p.Arg1314X) resulted in the deletion of exon 29 on RNA transcript 
level, which encodes the epitope of the rod-domain antibody and was therefore only 
recognized by the C-terminus antibody. As there was a good correlation between the 
dystrophin levels detected by the two antibodies (R 0·87; p<0·001) further analyses 
were performed using the C-terminus antibody. Using immune fluorescence analysis 
we observed homogeneous staining for most patients (16/22), generally at lower inten-
sity than the normal control. For a few patients we observed both dystrophin positive 
and negative fibres (5/22), while for one patient the biopsy was so fibrotic we did 
not observe any dystrophin staining (see Supplementary Figure 2 for representative 
examples).
strength measurements
QMA testing of elbow flexion and extension, handgrip and hip flexion and extension 
was performed in all patients. Due to inability to transfer to the research bench testing 
of knee flexion and extension was not possible in one and four patients respectively. 
A significant correlation existed between the MVIC-scores of all seven individually 
tested muscles. The mean MVIC-sum of the five muscle groups tested in all patients 
was 99 kg (± 59 kg, 15-186 kg). There was no significant relation between the MVIC-
sum score and the age of patients at the time of QMA-testing (R -0.15; p=0.41) (Fig-
ure 2a). However, when analysing our subgroup of thirteen patients with an exon 45-47 
Figure 1. Example of Western blot analysis on total protein extracts from three BMD patients and one 
healthy control. 
The rod-domain antibody (NCL-DYS1), C-terminus antibody (pABdys) and loading control (α-actinin) 
are shown. As anticipated from the deletions, the proteins in the BMD patients are slightly smaller than 
those in the healthy control. In the BMD group both patients with uniform and mosaic dystrophin ex-
pression were found by immunofluorescent staining.
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deletion a significant relation between MVIC-sum score and age was found (R -0.74; 
p=0.004). The mean MVIC-sum score of age-matched healthy male volunteers (mean 
age 42 ± 13 years, range 20-62 years) was 182 kg (± 23 kg, 142-220 kg), and showed 
no significant relation within this age range (R -0·41; p=0·07).
No relation was found between dystrophin expression and disease severity, as measured 
by MVIC-sum score in the whole group (R 0.30; p=0.13) or the exon 45-47 deleted 
subset (R -0.10; p=0.98) (Figure 2b). This relation was also absent when analysing 
all muscle groups individually. To decrease the possible confounding effect of age 
related differences in muscle strength, the analysis was subsequently performed in 
three subgroups: patients aged 18-30 (n=8), 31-45 (n=8) and 46 and older (n=11). No 
significant correlation between dystrophin levels and MVIC-sum score was present in 
Figure 2. Correlation between age (a. and c.) or dystrophin expression for the C-terminus antibody (b. 
and d.) with the MVIC-score and the mean fat fraction of the lower leg on MRI. 
Data of the subgroup with an exon 45-47 deletion are represented in closed dots, all other mutations in 
open circles. There is an evident relation for both the MVIC-score (a.) and the mean fat fraction (c.) with 
age of the patients in the deletion 45-47 subgroup (R -0.74; p 0.004 and R 0.92; p <0.001 respectively). 
No relation is found between dystrophin expression and MVIC-score (b.) or mean fat fraction on MRI 
(d.).
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any of these groups (R 0.40; p=0.33, R -0.30; p=0.47 and R 0.46; p=0.16 respectively). 
Analyses correcting for both age and weight were added using the z-scores calculated 
using data from Hogrel, showing again no correlation between dystrophin levels and 
muscle strength for the whole group (R 0.23; p=0.25) as well as the exon 45-47 sub-
group (R -0.71; p=0.83) [146].
Disease milestones
The median age of the disease milestones in 89 BMD patients (aged 3-66 years) was 
6 years for ‘first motor symptoms’, 20 years for ‘difficulties walking stairs’, 28 years 
for use of a walking aid and 33 years for wheelchair dependency. For each milestone 
we grouped our patients with known dystrophin levels based on whether that milestone 
presented before or after the median age of that milestone (Figure 3a). No significant 
differences were found between dystrophin levels of the two groups for ‘first motor 
symptoms’ (p=0.39), ‘difficulties walking stairs’ (p=0.91) and ‘use of a walking aid’ 
(p=0.25). As too few patients were wheelchair dependant, statistical analysis was not 
possible for this milestone. When this same analysis was repeated using three instead 
of two groups, with cut-off points based on the 33rd and 66th percentile of age at reach-
ing a certain disease milestones, no significant difference in dystrophin levels was 
present either (Figure 3b).
When analysing the exon 45-47 deletion subgroup the dystrophin levels were not 
significantly different for two disease milestones (p=0.94 and p=0.40 for first motor 
Figure 3. Distribution of dystrophin levels between patients reaching a disease milestone.
A. before or after the median age of that milestone and B. before the 33rd percentile, between the 33rd 
and 66th and after the 66th percentile of 89 BMD patients for first motor symptoms, difficulty walk-
ing stairs and use of a walking aid. The horizontal lines mark the average dystrophin level within the 
groups. Data for the patients with an exon 45-47 deletion are presented in black dots, data for all other 
patients in open circles. Note that grouping of a specific patient can be different for different milestones.
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symptoms and difficulties walking stairs, respectively). Too few patients had reached 
the other milestones to include these items in the analysis.
Muscle MRI
An MRI scan was obtained from nine patients with an exon 45-47 deletion. The lower 
leg showed a distinct pattern of muscle involvement, with the medial head of the 
gastrocnemius muscle being most severely affected, followed by the lateral head of 
the gastrocnemius and the peroneus muscle (Figure 4). The TA was relatively spared in 
all patients, but still showed a significant increase of the fat fraction with age (R 0·94; 
p<0.001). There was no correlation between dystrophin levels and fatty infiltration 
on MRI (R -0·03; p=0·95) (Figure 2d). There was however a significant correlation 
between patients’ age and mean fat fraction of the lower leg muscles (R 0·92; p<0·001) 
(Figure 2c).
Figure 4. Transversal image of lower leg of BMD patients with an exon 45-47 deletion. 
There is an evident increase in the mean fat fraction with age. The changes are most evident for the 
medial head of the gastrocnemius muscle and in later stages also for the lateral head.
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We studied a group of BMD patients with a large diversity in disease severity, as well 
as a wide range of different forms of dystrophin, with 18 different mutations, and as-
sessed dystrophin levels from freshly acquired muscle biopsies, with dystrophin levels 
ranging from 3 to 78%. In this group of BMD patients there was no linear relation 
between dystrophin levels and disease severity, defined by quantitatively measured 
muscle strength, fatty infiltration on MRI or by clinical milestones.
The relation between the variable disease severity observed in BMD patients and dys-
trophin levels has been of increasing interest with the development of exon skipping 
therapy for DMD patients. Although a small amount of dystrophin in muscle is better 
than none, it remains unclear what the relation between dystrophin levels and disease 
severity entails. Some previous studies found indications that higher dystrophin levels 
are associated with a milder disease course [150, 153, 154, 159, 161, 163]. Others 
reported a threshold effect [160, 162, 164]. However, these studies pooled data from 
patients with different mutations. Becker patients with in-frame deletions on the 5’-
end of the DMD gene generally have a more severe disease course, including an earlier 
age of cardiac involvement [159, 160, 167, 168]. Therefore, it is likely that the pooling 
of different mutations has influenced these results.
A recent study by Anthony et al. focused on a more selected group of patients with a 
mutation bordering exon 51 or exon 53 and patients with an exon 45-55 deletion, there-
fore limiting the effect of the location of the mutation on disease progression to some 
extent [154]. Their results suggested that higher dystrophin levels were associated with 
a less severe disease course. However, their analysis was performed in asymptomatic 
and mild patients with relatively high dystrophin levels (all above 50%). Therefore, the 
results cannot be extrapolated to the entire BMD disease spectrum. In our subgroup of 
13 patients with an exon 45-47 deletion no relation between dystrophin levels (varying 
from 13-76%) and disease severity was found. In contrast, in this subgroup there was 
an evident relation between disease severity and age of the patients. These findings are 
supported by the MRI data, showing a progressive increase in fatty infiltration with 
age. We believe this finding illustrates that the study of subsets of BMD patients with 
the same mutations can identify relations otherwise obscured.
Although we found no relation between dystrophin levels and disease severity, our 
four patients with dystrophin levels below 10% showed low MVIC-sum scores and 
early onset of symptoms (Figure 3 and Supplementary Table 1). This finding implies 
a threshold effect, which is conform several previous clinical studies suggesting that 
dystrophin levels below 10% are indicative of a more severe disease course [160, 162, 
164]. This could suggest that a relatively small amount of dystrophin is sufficient to 
result in a disease course that is milder than DMD, but relatively more severe than 
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‘typical BMD’. This is also in accordance with previous reports of several mouse 
models, showing threshold levels between 15-20%, and with a recent study in mice 
showing that in a dystrophin and utrophin negative background, very low levels of 
dystrophin (up to 5%) improved survival, but not histology, levels between 5 and 15% 
further improved survival and fibrosis and levels of over 15% normalized survival and 
further improved fibrosis [169-172]. The clinical disease course in patients with an 
exon 45-47 deletion was quite uniform, but still there was variability, suggesting a role 
for additional factors such as differences in regenerative capacity, genetic modifiers or 
inflammation.
Exons 45-47 encode the last half of spectrin-like repeat 17 as well as repeat 18 of the 
dystrophin protein. It is known that repeat 16 and 17 (encoded by exon 42-45) are 
involved in nNOS-binding [173, 174]. Anthony et al. and Beggs et al. both have shown 
a relationship between (properly located) nNOS levels and disease severity [154, 160]. 
Possibly, differences in nNOS expression could be one of the factors involved in the 
disease variability of the exon 45-47 deleted group.
As dystrophin plays an important role in muscle fiber membrane stability any change 
in protein structure could lead to a decreased functioning. The findings that in-frame 
mutations at the 5’-end of the DMD gene lead to a more severe BMD or a DMD 
phenotype suggest that this domain is less dispensable for protein function. In contrast 
the central rod domain that connects the N-terminal actin-binding and C-terminal beta-
dystroglycan binding domains allows more flexibility, as underlined by the finding 
that a deletion of >60% of the rod domain (deletion exon 17-48) resulted in a very 
mild BMD phenotype [175]. Structural changes of the dystrophin protein, caused by a 
specific mutation, will impair dystrophin function to an extent, characteristic for that 
mutation.
Our study suggests a direct effect of the exact mutation on the clinical phenotype 
of BMD patients. This finding has important implications for future BMD studies, 
where it will be essential to account for different mutations when looking at other 
possible contributing factors to disease severity. The possible disease modifying effect 
of dystrophin quality also has implications for exon skipping trials. As this therapy 
aims to change a DMD phenotype into a BMD phenotype, knowledge of the specific 
BMD phenotypes is important, as for some mutations ameliorating of the phenotype 
may be more beneficial than for others.
The suggestion of a threshold effect in this study could benefit therapeutic studies 
aiming to restore dystrophin in DMD patients. Clinical trials testing systemic delivery 
of antisense oligonucleotides targeting exon 51 have shown dystrophin levels of up 
to 18% [77, 79]. If relatively low levels of dystrophin are sufficient to result in a 
relatively mild BMD phenotype, it may be expected that patients may improve with 
these therapies.
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There are several limitations to our study. Firstly, several other studies used muscle 
biopsies from the quadriceps muscle, while we chose to biopsy the anterior tibialis 
muscle, as it contains viable muscle tissue over wider clinical severity. Variation in 
dystrophin expression between muscles cannot be ruled out, but there are no indica-
tions that this could limit the interpretation. A previous immunohistochemical study 
reported no significant variation in dystrophin levels between various muscles in DMD 
patients, nor between biceps brachialis and vastus lateralis muscles in a group of BMD 
patients [159, 176]. Additionally, no significant variation in dystrophin expression was 
found in different skeletal muscles in mice [177]. Although our study is the largest study 
in BMD patients comparing disease course and dystrophin levels using fresh biopsies, 
our study could be underpowered to detect a possible relation between dystrophin 
levels and disease severity. Larger subgroups of BMD patients with the same mutation 
would be necessary to study such a relation, which, due to the rareness of BMD, will 
be challenging. However, in our subgroup of patients with an exon 45-47 deletion 
we did find a relation with age, but not with dystrophin. Thirdly, although there is no 
significant difference in disease course between participants and non-participants, a 
small trend favouring the participation of milder patients appears to be present. This 
is probably caused by the greater burden on severely affected patients to participate.
In summary, our study shows that there is no linear correlation between dystrophin 
levels and disease severity in BMD patients and that disease progression is uniform in 
a subgroup of BMD patients with an exon 45-47 deletion, as demonstrated by the de-
crease of muscle strength as well as increase of fatty infiltration of muscle. In contrast 
to the whole BMD group, these phenomena increase with age at a constant pace in the 
exon 45-47 deletion group, indicating that the mutation is likely an important factor in 
determining disease severity. Furthermore, there are indications for a threshold rather 
than a dose-effect relation and the fact that this threshold could likely be around 10% 
of normal levels (at least for the exon 45-47 deletion) has important implications for 
therapeutic approaches aiming at dystrophin restoration.
Chapter 4
60
supplementary table 1: Overview of data and clinical characteristics of study participants (¹ brothers).




















1 del 45-47 47 Yes No 117 23 6 38 43 -
2 del 45-47 51 Yes No 94 30 5 18 51 -
3 del 45-47 26 Yes Yes 179 13 21 - - -
4 del 45-47 63 Yes Yes 54 19 25 30 35 60
5 del 45-47 47 Yes No 54 21 17 19 25 37
6 del 45-47 39 Yes Yes 80 56 5 20 38 -
71 del 45-47 37 Yes Yes 113 76 16 20 30 -
8 del 45-47 20 Yes No 165 37 6 - - -
9 del 45-47 29 Yes Yes 73 66 12 20 - -
10 del 45-47 39 Yes Yes 125 74 21 35 - -
111 del 45-47 33 Yes Yes 140 29 25 28 - -
12 del 45-47 43 No Yes 64 NA 6 35 35 -
13 del 45-47 31 Yes Yes 129 62 2 - - -
14 del 03-04 31 Yes No 88 35 6 25 25 -
15 del 03-05 33 Yes No 102 32 18 25 - -
16 del 03-07 57 Yes No 15 10 4 12 40 45
17 del 05 19 Yes No 40 4 2 4 4 10
18 del 10-22 47 Yes No 82 38 6 20 37 -
19 del 10-30 30 No No 52 NA 4 4 20 -
20 dup 14-42 66 Yes No 65 23 18 60 65 -
21 Exon 19: 
c.2380+3A>C
29 Yes No 55 3 2 4 9 25
22 Exon 26: 
c.3515G>A; 
p.Trp1172X
30 Yes No 121 15 6 25 - -
23 Exon 29: 
c.3940C>T;p.
Arg1314X
38 Yes No 159 14 - - - -
24 del 45-55 51 Yes No 185 40 6 - - -
25 del 45-49 32 No No 24 NA 8 18 20 27
26 del 48-49 42 No No 186 NA 11 - - -
27 del 30-44 24 Yes No 61 7 12 21 - -
28 del 45-48 49 No No 60 NA 12 30 25 -
29 del 45-48 48 Yes No 113 43 15 30 35 49
30 del 45-48 51 Yes No 36 59 4 13 25 39
31 del 48-49 25 Yes No 161 78 - - - -
32 Unknown 56 Yes No 156 56 18 50 - -
33 del 45-55 63 No No 124 NA 6 43 63 -
(NA: data not available, hyphen in section: patient has not reached the specific milestone).
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supplementary Figure 1. Average dystrophin levels assessed by Western blot for BMD patients.
Protein was isolated from muscle biopsies and dystrophin levels were quantified by quantitative West-
ern blotting using the Odyssey system setting dystrophin levels observed in healthy muscles to 100% 
and using alpha-actinin to correct for equal loading. Each sample was measured at least two times with 




supplementary Figure 2. Immunofluorescent staining for dystrophin.
Dystrophin staining is continuous and bright for the healthy control (top left panel). Representative 
images of cross sections from BMD patiens are shown, showing either continuous staining at a lesser 



















































t2 relaxation times are increased 
in skeletal muscle of DMD 
but not BMD patients
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Exon-skipping drugs in Duchenne muscular dystrophy (DMD) aim to restore truncated 
dystrophin expression, which is present in the milder Becker muscular dystrophy 
(BMD). MRI skeletal muscle T2 relaxation times as a representation of oedema/
inflammation could be quantitative outcome parameter for such trials.
Methods
We studied T2 relaxation times, adjusted for muscle fat fraction using Dixon MRI, in 
lower leg muscles of DMD and BMD patients and healthy controls.
Results
T2 relaxation times correlated significantly with fat fractions in patients only (p<0.001). 
After adjusting for muscle fat, T2 relaxation times were significantly increased in 6 
muscles of DMD patients (p<0.01), except for the extensor digitorum longus. In BMD, 
T2 relaxation times were unchanged.
Discussion
T2 relaxation times could be a useful outcome parameter in exon-skipping trials in 
DMD but are influenced by fat despite fat suppression. This should be accounted for 
when using quantitative T2 mapping to investigate oedema/inflammation.
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Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are 
X-linked muscle diseases caused by a mutation in the dystrophin encoding DMD 
gene [10]. As a result there is generally no functional dystrophin in DMD patients and 
shortened, partially functional dystrophin in BMD patients. Initially muscle fibers un-
dergo processes of degeneration and regeneration accompanied by inflammation in the 
muscle. As the regenerating capacity of the muscle progressively disappears, muscle 
fibers are increasingly replaced by adipose and fibrotic tissue [38, 54, 113]. However, 
the exact pathophysiological process underlying the progressive muscle damage is not 
understood fully [65, 178]. Clinically, both DMD and BMD patients have progressive 
muscle weakness, predominantly in proximal limbs in early stages of the disease, with 
more generalized weakness later on. DMD patients become wheelchair-bound in their 
early teens and die prematurely due to cardiac or respiratory failure, whereas BMD 
patients have a more variable and usually less severe disease course [136].
Although there is no curative therapy available for DMD, several clinical trials aim to 
restore expression of truncated dystrophin using antisense oligonucleotide-mediated 
exon skipping [77, 78, 117]. This would potentially change the DMD patients into a 
milder phenotype similar to BMD patients. As a result, there is interest in objective and 
reliable tools to assess outcome measures for patients of different ages and at different 
disease stages. Quantitative magnetic resonance imaging (MRI) could be such a tool, 
as it is non-invasive, has good spatial resolution over a large imaging plane, can be ap-
plied repetitively, and has shown promise in monitoring disease progression in DMD 
[103-106, 108, 113, 114, 179, 180]. Inflammation is present in both DMD and to a 
lesser extent in BMD from early disease stages when muscle damage is less extensive 
and is considered potentially reversible in contrast with fatty infiltration [17, 181]. As 
such, assessment of inflammation could be a valuable outcome parameter, especially 
as therapies would preferably start in young patients who have minimal irreversible 
structural changes [108].
In MRI, the proton transverse relaxation time (T2) depends on the presence of oedema/
inflammation as well as the level of fatty infiltration in muscle. T2 relaxation times 
in inflamed muscle are longer than relaxation times of normal muscle tissue and the 
T2 relaxation times in muscles with fatty infiltration are even longer [90, 103, 182]. 
Therefore, especially in fat infiltrated muscle, it is essential that the fat is taken into 
account in the analysis, as otherwise it is unknown to what extent longer T2 relaxation 
times are a result of increased fat fractions or due to oedema/inflammation [183]. 
Several studies have quantitatively measured the T2 relaxation times in DMD patients 
and found it to be increased [90, 109, 114]. However, without fat suppression it is 
unknown to what extent the observed longer T2 relaxation times result from increased 
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fat fractions or oedema/inflammation [183]. Two recent studies sought to circumvent 
this problem by applying fat suppression in quantitative T2 images in a subset of their 
DMD patients [103, 108]. Unfortunately, fat suppression does not always suppress the 
entire fat signal present in skeletal muscle, and hence the results could still have been 
influenced by increased fat fractions [183]. Similar MRI studies assessing oedema/in-
flammation have not been done in BMD patients. To evaluate if the T2 relaxation time 
could be a possible outcome parameter in clinical trials, a better understanding of how 
changes in muscle of DMD patients relate to BMD patients is needed. Therefore, the 
aim of our study was to compare T2 relaxation times in lower leg muscles of DMD and 
BMD patients and healthy controls, while taking the increased fat levels into account.
MethoDs
subjects
DMD and BMD patients were recruited from the Dutch dystrophinopathy database. 
The diagnosis of DMD or BMD had been confirmed by genetic testing for mutations 
in the DMD gene or from a muscle biopsy. Healthy age-matched controls were re-
cruited from local schools and from the Leiden University Medical Center Radiology 
database for healthy controls. The local medical ethics committee approved the study, 
and informed consent was obtained from all subjects. For participants under age 18, 
informed consent was obtained from both the subjects and their parents.
MRI
MR images were acquired on a 3T Philips Achieva Scanner (Philips Healthcare, Best, 
The Netherlands) from the left lower leg using a 14-cm 2-element receive coil with 
body coil excitation. The receive coil was positioned directly distal to the patella on 
the anterior and posterior sides of the leg. The scanning protocol consisted of a T1-
weighted turbo spin echo (TSE) sequence [25 slices, 5 mm thickness, 0.5 mm gap, 
repetition time (TR) 600 ms, initial echo time (TE) 16ms, TSE factor 5], a 3-point 
gradient echo Dixon sequence (25 slices, 5 mm thickness, 0.5 mm gap, TR 400 ms, 
TE 4.41 ms, echo spacing 0.71 ms, flip angle 8˚) and a multi-echo sequence with fat 
suppression for quantitative T2 mapping [5 slices, 5 mm thickness, 22.5 mm gap, TR 
2500 ms, 7 echo times (13, 26, 39, 52, 65, 78 and 91 ms), flip angle 90˚, spectral pre-
saturation with inversion recovery (SPAIR) fat suppression] using a mono-exponential 
fit and maximum likelihood estimation [118, 122]. The total scanning protocol, includ-
ing positioning of the patients, could be completed in 20 minutes.
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T2 values were calculated using a maximum likelihood estimation algorithm supplied 
by the scanner manufacturer. Regions of interest were drawn using Medical Image Pro-
cessing, Analysis and Visualization software (www.mipav.cit.nih.gov) on the second, 
third, and fourth slices of the shortest echo image and superimposed on the calculated 
T2 maps to obtain the mean T2 values of the following muscles: medial and lateral 
head of gastrocnemius muscle (GCM and GCL), soleus (SOL), posterior tibialis (TP), 
Figure 1. Axial image of lower leg showing the first echo time of the quantitative T2 image of a 12 year-
old DMD patient (a), a 63 year-old BMD patient, and (c) a Dixon water image of the DMD patient (b), 
and the BMD patient (d). 
The Dixon image clearly shows diffuse fatty infiltration in virtually all muscles in the DMD patient, 
whereas in the BMD patient the medial gastrocnemius is most severely affected while the other muscles 
are still relatively spared.
Muscles shown are medial gastrocnemic muscle (GCM), lateral gastrocnemic muscle (GCL), soleus 
muscle (SOL) posterior tibialis muscle (TP), anterior tibialis muscle (TA), extensor digitorum longus 
muscle (EDL) and fibularis muscle (FIB).
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fibularis (FIB), anterior tibialis (TA), and extensor digitorum longus (EDL) (Figure 1). 
Dixon images were co-registered to T1 images, on which regions of interest in every 
other slice were drawn for the previously mentioned muscles. The middle 11 slices 
were used to cover the same FOV from which the T2 relaxation times were calculated. 
Fat and water images were generated using multipeak fitting, and fat fractions were 
calculated as described previously [143].
statistical analysis
One-way between-groups analysis of covariance (ANCOVA) was conducted to com-
pare the T2 values in patients and controls. Disease status was used as fixed factor, and 
fat percentage and age were used as covariates. By including the muscle fat fraction 
as a covariate the T2 relaxation times adjusted for fat fractions could be calculated 
and were subsequently incorporated in the analysis. A Bonferroni-Holm model was 
used to correct for multiple comparisons. A Pearson correlation was performed to test 
the relationship between fatty infiltration and T2 relaxation time in DMD and BMD 
patients and in healthy controls. SPSS statistical package Version 20.0 for Windows 




Nineteen DMD patients (age 10.5±2.7, range 6-14 years), 11 healthy boys (age 
10.7±2.1, range 8-15 years), 7 BMD patients (age 39.6±11.7, range 26-63 years), and 
8 healthy male adults (age 34.4±12.6, range 24-62 years) participated in the study, 
and all completed the protocol. Of the DMD patients, 10 were fully ambulant, 2 used 
a wheelchair intermittently, and 7 were completely wheelchair dependent. All but 3 
DMD patients used corticosteroids: an 8-year old boy who was still completely mo-
bile and had never used steroids and 2 13-year old boys who were both wheelchair 
dependent and had been on steroids for approximately 5 years, but had stopped 1 and 
2 years, respectively, prior to this study. Of the BMD group, 2 men (aged 26 and 38) 
experienced no problems or weakness in their daily activities. Three patients (aged 
63, 39, and 31) reported muscle weakness when carrying out daily activities such as 
climbing stairs, but none required a walking aid. Two patients (aged 37 and 43) were 
completely wheelchair-dependent. All BMD patients experienced occasional muscle 
cramps.
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To adjust for potential effects of fatty infiltration on the T2 values, the fat fractions for 
the analysed muscles were calculated using Dixon MRI. The mean fat fraction of all 
analysed muscles was 20.7±7.0% for DMD patients, 5.6±0.9% for paediatric controls, 
15.3±11.8% for BMD patients, and 4.4±0.5% for adult controls. Of the analysed 
muscles, the GCL had the highest mean fat fraction in DMD patients (28.4%), and the 
TP had the lowest (8.2%). In the BMD patients, the GCM had the highest mean fat 
fraction (31.8%), and the TA had the lowest (2.2%).
t2 relaxation times
There was a significant correlation between unadjusted T2 values and fatty infiltra-
tion in the DMD and BMD patients (R=0.70, p<0.001), but not for healthy controls 
(R=1.13, p=0.15) (Figure 2). Uncorrected average T2 relaxation times in DMD pa-
tients were 43±2.4 ms, 42±4.2 ms in BMD patients, 36±1.4 ms in paediatric controls, 
and 38±1.8 ms in adult controls. After adjusting for the fat percentage the average T2 
relaxation times were 42.2±2.2 ms in DMD patients, 39.1±3.3 ms in BMD patients, 
37.3±1.4 ms in paediatric controls, and 39.8±2.6 ms in adult controls. The adjusted T2 
relaxation times were significantly higher in DMD patients compared to controls for 
the GCM, GCL, SOL, and TP (all p<0.001), TA (p=0.005) and FIB (p=0.002), but not 
for the EDL (p=0.96) (Figure 3). There were no significant differences between BMD 
patients and controls after adjusting for the fatty infiltration in any of the investigated 
muscles (Figure 3).
Figure 2. Correlation between fatty infiltration and fat suppressed T2 values in DMD patients (open 
circles) and BMD patients (grey dots). 
Although fat suppression was applied, there remains a significant influence of the fatty infiltration on the 




In this study we show that in DMD patients the T2 relaxation times, with adjustment 
for the increased fat percentage, are significantly increased compared to healthy boys in 
all analysed muscles except the extensor digitorum longus. In contrast, BMD patients 
did not show significant increases in adjusted T2 values compared to healthy controls. 
This suggests that the T2 relaxation time could be a useful outcome parameter in DMD 
trials that aim to restore truncated dystrophin expression, which is typically expressed 
in BMD patients.
Increased T2 relaxation times in skeletal muscle can originate from a number of 
factors, including inflammation, necrosis, or moderate-severe exercise [183]. The 
T2 relaxation time has also been shown to increase with age [184]. In muscle tis-
sue of DMD and BMD patients mononuclear cell infiltrates predominantly consist of 
T-lymphocytes and macrophages [54-56, 181, 185]. Several mechanisms have been 
hypothesized to contribute to the inflammation. It has been suggested that inflamma-
tion is a non-specific event, which could be triggered by surrounding necrotic muscle 
fibers [55, 59]. Activation of an immune response via toll-like receptors triggered by 
myofiber damage before more structural changes are present is believed to be another 
explanation [55, 62]. A specific cellular autoimmune response to an unknown antigen 
has also been suggested [61]. The various components involved in the inflammatory 
response are thought to contribute directly to some of the muscle damage [56, 62, 63, 
185, 186]. In addition to the potential effects of inflammation, a recent sodium MR 
study demonstrated oedema-like changes in muscle of DMD patients and suggested 
that increased intracellular sodium might also play a direct role in the pathogenesis of 
Figure 3. Mean adjusted T2 relaxation times ±SD of DMD patients (black) versus controls (dark grey) 
(a) and BMD patients (checked) versus controls (light grey) (b) of the investigated muscles [medial and 
lateral heads of gastrocnemius (GCM, GCL), soleus (SOL), anterior tibialis (TA), extensor digitorum 
longus (EDL), fibularis (FIB) and posterior tibialis (TP)). Muscles with significantly different T2 values 
are shown with an asterisk (*).
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progressive muscle degeneration[187]. These mechanisms could all contribute to an 
increase in the T2 relaxation time, as observed in our DMD patients
In contrast to DMD patients, there are no specific anatomical pathology studies 
describing to what extent inflammatory processes contribute to muscle degeneration 
in BMD patients. As BMD patients have some, albeit not full-length, dystrophin it 
could be that the mechanism(s) causing inflammation are less prominent compared to 
DMD patients. This is supported by the observation that inflammation is less in muscle 
biopsies of BMD patients than in DMD patients [17, 181]. This could explain why no 
significant increase in adjusted T2 relaxation time was seen in our BMD patients.
While several studies have quantitatively measured the T2 relaxation times in DMD 
patients and found it to be increased [90, 109, 114], only two recent studies described 
increased T2 relaxation times in lower leg muscles of DMD patients using fat suppres-
sion[103, 108]. Our results show that even though fat is suppressed using SPAIR, the 
T2 values and level of fatty infiltration were correlated in many of the investigated 
muscles. Therefore, an influence of the lipid signal on the T2 values in previous studies 
cannot be ruled out. Recently, it was shown that suppressing fat with just SPAIR aimed 
at the aliphatic fat region around 2.6 parts per million is not sufficient to eliminate the 
entire fat signal[188]. This could be solved by using additional methods to suppress 
the olefinic fat signal [188, 189]. Alternatively, applying proton MR spectroscopy 
and separately assessing the T2 relaxation time of water and fat can circumvent this 
problem. However, this will only yield results over a small volume of interest and is 
too time consuming to perform for a large number of muscles. Thirdly, a chemical shift 
method can be employed in which water and fat images are obtained at multiple echo 
times, but unfortunately this sequence is not currently available on all commercial MR 
scanners [190]. Finally, water and fat can be separated in post-processing, as proposed 
by several authors [145, 183, 191-193], or by adjusting for the fat by statistical analy-
sis, as we have done here.
Several previous studies have suggested the use of the fatty infiltration in DMD pa-
tients as a measure of disease progression and potential outcome parameter [103, 104, 
106, 194]. In the dystrophic process, oedema/inflammation is thought to occur prior to 
fatty infiltration and could therefore be used as an earlier marker of therapy effective-
ness compared to changes in levels of fatty infiltration. In addition, it is questionable 
if severely fatty infiltrated muscles can still be rescued, and as such fatty infiltration in 
these patients might be irreversible. Alternatively oedema/inflammation is potentially 
more likely to be reversible and could therefore be of value as an outcome parameter 
in assessment of future therapies, especially in early disease stages when effect of the 
lipid signal on the T2 relaxation times is minimal.
Recently it has been suggested that T2 relaxation times in DMD patients are reduced as 
a function of age [115, 195, 196]. However there remains some discussion as to these 
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findings, since some authors report a decrease and others report an increase [103, 108]. 
The cause for this potential decrease is still uncertain and could be due to technical 
reasons or pathophysiology, i.e. a decrease in oedema or an increase in fibrosis. So far 
the available data imply that if the T2 relaxation times decrease, they do not normalize 
to the levels of healthy controls, and they have only been described for older DMD 
patients. Therefore, even if such an effect were to be present, the T2 relaxation time 
remains a potential valuable parameter in the follow-up of younger patients.
This study has some limitations; firstly, the group of BMD patients participating in the 
study was relatively small. However, as we obtained data from several muscles ranging 
from patients with very few clinical symptoms to wheelchair-dependent patients we 
felt that our findings are likely to be representative of the whole spectrum of the dis-
ease. Secondly, 3 of our DMD patients did not use corticosteroids. Although a previous 
study showed no significant effect on the T2 relaxation time in DMD patients before 
and after steroid treatment, a recent report suggested that corticosteroids do in fact 
result in a decrease of the T2 relaxation time [114, 197]. However, a reduction of the 
T2 relaxation time as an effect of steroids would decrease possible differences between 
patients and controls. As the number of steroid-free patients in our cohort was very 
small, it is unlikely that the patients not on steroids represented the sole contribution to 
the significant difference between patients and controls. Thirdly, a TR of 2500ms was 
used to avoid very long acquisition times, which result in partial saturation effects due 
to the long T1 of water. Finally, we only assessed the lower leg in our study, as the B1 
field in this region is much more homogeneous compared to the upper leg. However, 
the upper legs are known to be involved earlier in both DMD and BMD patients. For 
future studies it would be valuable to compare proximal muscles in either the leg or 
arm of both DMD and BMD patients.
In conclusion, we show that skeletal muscle T2 relaxation times are significantly in-
creased in DMD patients, which is indicative of the presence of inflammation/oedema. 
We also show no such increase is present in the generally less severely affected BMD 
patients. Therefore we believe that quantitative T2 mapping, while taking the lipid 
signal into account can be a useful method for evaluation of oedema/inflammation 
of DMD patients and could be an outcome parameter in treatment trials aiming to 



















































Muscle spectroscopy detects 
elevated PDe/AtP ratios prior 
to fatty infiltration in Becker 
muscular dystrophy patients
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Becker muscular dystrophy is characterized by progressive muscle weakness. Muscles 
show structural changes (fatty infiltration, fibrosis) and metabolic changes, both of 
which can be assessed using MRI and MRS. It is unknown at what stage of the disease 
process metabolic changes arise and how this might vary for different metabolites. In 
this study we assessed metabolic changes in skeletal muscles of Becker patients, both 
with and without fatty infiltration, quantified via Dixon MRI and 31P MRS. MRI and 
31P MRS scans were obtained from twenty-five Becker patients and fourteen healthy 
controls using a 7T MR scanner. Five lower leg muscles were individually assessed for 
fat and muscle metabolite levels. In the peroneus, soleus and anterior tibialis muscles 
with non-increased fat levels PDE/ATP ratios were higher (p<0.02) compared to 
controls, whereas in all muscles with increased fat levels PDE/ATP ratios were higher 
compared to healthy controls (p≤0.05). The Pi/ATP ratio in the peroneus muscles was 
higher in muscles with increased fat fractions (p=0.005) and the PCr/ATP ratio was 
lower in the anterior tibialis muscles with increased fat fractions (p=0.005). There were 
no other significant changes in metabolites, but an increase in tissue pH was found in 
all muscles of the total group of BMD patients in comparison with healthy controls 
(p<0.05). These findings suggest that 31P MRS can be used to detect early changes in 
individual muscles of Becker muscular dystrophy patients, which are present before 
the onset of fatty infiltration.
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Becker muscular dystrophy (BMD) is an X-linked disease caused by mutations in the 
DMD gene, which codes for the dystrophin protein, an important factor for muscle 
membrane stability [10]. In BMD patients the dystrophin protein is only partially 
functional, resulting in continuous muscle fiber damage. There is inflammation and 
oedema in the muscle and eventually the muscle cells’ regenerative capacity becomes 
exhausted and muscle tissue is replaced by adipose and fibrotic tissue [38, 54]. The 
main feature of the disease is progressive muscle weakness with a limb-girdle distribu-
tion, but symptoms can be highly variable in age of onset, severity of symptoms and 
rate of progression [159, 160]. The underlying mechanisms causing the variability are 
not fully understood and are thought to include factors like the regenerative capacity 
of the muscle, quantity of the remaining dystrophin protein and the specific mutation 
[154-157, 198].
Skeletal muscles of BMD patients show a distinct pattern of fatty infiltration, which 
can be assessed with magnetic resonance imaging (MRI) [199]. With the progression 
of the disease the amount of adipose tissue in the muscle increases, and muscles of 
clinically asymptomatic patients can already show fatty infiltration in some muscles, 
while others still appear to be normal [199]. In addition to these structural changes in 
the muscle, several phosphorus MR spectroscopy (31P-MRS) studies have reported 
changes in BMD patients suggestive of an altered energy metabolism [92, 95, 200, 
201]. However, the results of these studies have been inconsistent; both unchanged and 
decreased phosphocreatine (PCr) to adenosine triphosphate (ATP) ratios, increased, 
unchanged and decreased inorganic phosphate (Pi)/ATP ratios and an unchanged and 
increased intracellular pH and possibly increased phosphodiesters (PDE)/ATP ratios 
have been reported [92, 94, 95, 200, 201]. Mitochondrial function is believed to be 
normal in these patients and it has been suggested that there is reduced glycolytic ac-
tivity in the skeletal muscles [95, 200]. While structural changes like fatty infiltration 
and fibrosis are predominantly present in muscles that are in a more advanced stage of 
the dystrophic process, metabolic changes are thought to occur earlier [202]. However, 
it is unknown if and how metabolic changes contribute to the muscle degeneration 
and to what extend these changes are present before the occurrence of fatty infiltra-
tion. Previous studies in BMD patients have focused on the more severely affected 
gastrocnemic muscles using surface coil localization only, without the combination 
of imaging data and patients with variable disease severity. Therefore it is unknown if 
the reported changes in phosphorous metabolism in BMD patients are already present 
in muscles without fatty infiltration, i.e. a less advanced stage of the disease before 
signs of the dystrophic process are visible with MRI. Since metabolic processes are 
more likely to be reversible than structural changes like fatty infiltration they could 
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be valuable as an early marker to evaluate disease progression and possibly effects of 
future therapeutic interventions [110, 203-205].
In this study, we used high magnetic field quantitative MRI and MRS in BMD patients 
and healthy controls to assess phosphorous metabolism in five individual lower leg 
muscles, and correlated the findings to the level of fatty infiltration obtained from the 




All patients were recruited from the Dutch Dystrophinopathy Database. Controls 
were recruited from the Leiden University Medical Center Radiology database for 
healthy controls. The diagnosis BMD was confirmed by a mutation in the DMD gene 
or reduced dystrophin expression in a muscle biopsy. BMD patients were classified 
into four groups according to their clinical functioning: no motor symptoms, mildly 
affected (patients with difficulty walking and/or difficulty climbing stairs, but not us-
ing a walking aid), moderately affected (patients using a walking aid: stick, frame or 
intermittent wheelchair use), and severely affected patients (completely wheelchair 
dependent).
The local medical ethics committee approved the study and all study participants gave 
written informed consent.
MR examination
Data were acquired on a 7T Philips Achieva MRI (Philips Healthcare, The Nether-
lands). A custom-built volume birdcage coil (diameter 17.5 cm, length 12 cm) tuned 
for both proton (1H) imaging (higher order mode) and phosphorous (31P) spectroscopy 
(homogeneous quadrature mode) was positioned around the left lower leg directly 
distal of the patella [206]. Patients were positioned in supine position, feet first, in the 
scanner. The imaging protocol consisted of an anatomical gradient echo sequence (15 
slices; slice thickness 7mm; interslice gap 0.5 mm; repetition time (TR) 10 ms; echo 
time (TE) 3.0 ms; flip angle (FA) 30°; FOV 180x200 mm) a three-point gradient echo 
Dixon sequence (12 slices; slice thickness 10 mm; interslice gap 0.5 mm; TR/TE/ΔTE 
300/2.4/0.33 ms; FA 30°; FOV 180x204 mm) and a B0 map (14 slices; slice thickness 
8 mm, no slice gap; TR/TE 30/3.11ms; FA 20°; FOV 160x180 mm). A 2D phosphorous 
MRS chemical shift imaging (CSI) dataset was acquired based on the T1-weighted 
images (FOV 160x200 mm; matrix size 8 x 10; TR 2000 ms; samples 2048; voxel 
size 20x20 mm; FA 45°; Hamming weighted acquisition with 14 signal averages at 
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the central k-lines, voxel size after hamming weighing 3.42x3.42 x12 cm3). Second 
order shimming was performed using an image based shimming routine [207]. As the 
diameter of the lower leg and the boundaries between the different muscle groups 
change along the length of the leg, the 2D-CSI sequence was planned in such a way 
that within the volume of the coil a specific voxel was located within one individual 
lower leg muscle (Figure 1). The total scan duration was approximately 50 minutes. 
For quality control of the 7T Dixon data the 7T values were compared to Dixon MRI 
data acquired from the same patients on a 3T Philips Achieva scanner in a subgroup of 
9 patients previously described by Van den Bergen et al. [198]. Data of these patients 
was obtained on the same day, from the same leg using a 14-cm diameter two-element 
coil with body coil excitation position directly distal of the patella.
Data analysis
31P Data sets were visualized using the 3D Chemical Shift Imaging package (3DiCSI) 
and spectra were identified in the tibialis anterior (TA), peronei (PER), soleus (SOL), 
lateral head of the gastrocnemius (GCL) and medial head of the gastrocnemius (GCM) 
muscles using a grid overlay on the T1-weighted image (Figure 2). Voxels were care-
fully positioned to avoid overlap with adjoining muscles.
The free induction decays were exported and fitted using AMARES in jMRUI software 
package (version 4, http://sermn02.uab.es/mrui). In some patients high amounts of 
fatty infiltration within the muscle resulted in a low signal-to-noise in the phosphorous 
spectra due to the very low amount of muscle tissue in the voxel. Consequently only 
Figure 1. Example of the planning of the 31P 2D-CSI dataset superimposed on an axial T1 weighted 
image. 
The spectroscopy grid was positioned so that specific voxel was located within one individual lower leg 
muscle over the entire length of the coil: in the first (a.), middle (b.) and last slice (c.) of the T1-weighted 
image the voxel in the tibialis anterior muscle as well as the voxel in the soleus muscle lies within the 
same muscle over the length of the coil.
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the muscles with an acceptable quality spectrum (i.e. SNR greater than 10 for the PCr 
peak in combination with the ability to identify all other metabolite signals and with 
percentage Cramér-Rao Lower Bound (CRLB) values for all fitted metabolites below 
20%) were included in the analysis. Signals of Pi, PDE, PCr and γ-, α- and β-ATP 
were fitted with Gaussian line shapes (Figure 3). For the PDE and β-ATP peak prior 
knowledge on the line width was used. The line width for PDE was set at 1.3* the line 
width of PCr and the β-ATP line width was set at 1.6* the line width of α-ATP, this 
prior knowledge was based on the mean line widths of 10 patients with high SNR. 
Metabolite ratios were obtained from Pi, PDE and PCr relative to the γ- ATP signal 
and corrected for 1H relaxation effects measured in human calf muscle at 7T assum-
ing the same relaxation parameters for all muscles [208]. Intracellular tissue pH was 
calculated from the shift in resonance position (S) of the Pi peak compared to PCr: 
pH=6.75 + log ((3.27-S)/(S-5.69)) [209].
Quantitative fat fractions of the muscles were calculated from the Dixon MR images 
using Medical Image Processing, Analysis and Visualization (MIPAV) software (http://
mipav.cit.nih.gov). Regions of interest (ROIs) were drawn on all slices, on the same 
muscles as used for the spectroscopy analysis. Fat fractions were calculated as signal 
intensity (SI) fat/ (SI fat+ SI water))*100. 3T values were corrected for relaxation 
effects as described before [143]. For the comparison of 3T and 7T data, fat fractions 
Figure 2. Grid overlay on an axial Dixon water-image of the lower leg of a BMD patient. 
Spectra were analysed in the anterior tibialis, peroneus, soleus and medial and lateral head of the gas-
trocnemic muscle for which the ROIs are drawn on the image. Voxels of the CSI-grid were carefully 
positioned to avoid overlap with adjoining muscles. Note that the coil used for this image is a single 
tuned birdcage coil, with the primary homogeneous mode being at the phosphorus frequency and a 
higher mode at the proton frequency, resulting in a loss of sensitivity in the center of the coil for proton, 
but not for phosphorous.
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obtained from the TA, PER, SOL, GCL and GCM muscles from a similar number of 
slices from both scanners were compared on a muscle-by-muscle basis.
All individual muscles of the Becker patients were classified into two groups according 
to the level of fatty infiltration compared to healthy controls; BMD with non-increased 
fat levels (NIFL)), and BMD with increased levels of fatty infiltration (IFL). Cut-
off values were calculated for the five individual lower leg muscles using mean+2 
standard deviations (SD) of the fat fraction of the corresponding lower leg muscle of 
healthy controls.
statistics
For the comparison of the metabolite ratios Pi/ATP, PCr/ATP, PDE/ATP, Pi/PCr and pH 
between the groups for the five lower leg muscles two general linear models were used, 
one for the comparison of healthy controls with the whole group of BMD patients and 
one for the comparison of healthy controls with the NIFL BMD and IFL BMD groups. 
Age was entered as a covariate and disease as a fixed factor. A Fischer LSD model was 
used to correct for multiple comparisons. Pearson correlation was used for the com-
parison of the Dixon scan data acquired at 3T and 7T to explore the relation between 
fat fractions and the PDE/ATP ratio in both healthy controls and BMD patients. The 
level of significance was set at P≤0.05. Statistical analysis was performed using SPSS 
version 20 for Windows (SPSS Inc., Chicago).
Figure 3. Representative phosphorous 7T spectra of the peroneus muscle in a healthy control, BMD 
patient with non-increased fat fractions (BMD NIFL) and BMD patient with increased fat fractions 
(BMD IFL). 
Spectra are scaled to the ATP levels. The signal to noise ratio of the 31P signal clearly decreases in the 
BMD patient with increased fat levels. Peak assignments Pi = inorganic phosphate, PDE = phosphodies-





Twenty-five male BMD patients (age 39.6 ± 13 years, range 20-66, BMI 25.04 ± 3.65, 
range 20-33) and fourteen age-matched healthy male controls (age 35.7 ± 15 years, 
range 22-65, BMI 22.64 ± 3.37 range: 20-32.4) participated in the study. All subjects 
completed the scanning protocol. Of the 25 BMD patients five patients had no motor 
symptoms, eleven were mildly affected, seven moderately affected and two severely 
affected (Table 1). Four of the patients with no motor symptoms showed normal fat 
levels on Dixon MRI and one patient with no motor symptoms showed a slightly 
increased fat fraction in the GCM and GCL. The GCM and GCL showed increased 
fat levels in all moderately affected patients and fat fractions were increased in all 
investigated muscles of severely affected patients (Table 1).
Fatty infiltration
The mean fat level in healthy controls was 2.9 ± 1.1% and in patients 16.0 ± 18.6%. 
Overall the GCM showed the highest mean fat fractions and the SOL the lowest. Mus-
cles with fat fractions lower than the mean fat fraction plus 2 SD in the corresponding 
muscle of healthy controls were defined as muscles with no significant increase in 
fatty infiltration and classified in the non-increased fat levels (NIFL) group. The other 
muscles were classified in the group with increased levels of fatty infiltration (IFL), as 
compared to healthy controls (Table 1). The fat fractions calculated from five muscles 
of nine BMD patients acquired at 3T and 7T showed a high correlation (R=0.97).
31P data
All metabolite ratios of the healthy controls and BMD patients are shown in Table 2. 
For the analysed muscles the NIFL/IFL subgroups were divided as follows; GCL NIFL 
n=5/IFL n=13 (cut-off fat fraction 3.4%), GCM NIFL n=5/IFL n=9 (cut-off 4.5%), 
PER NIFL n=10/IFL n=15 (cut-off 6.8%), SOL NIFL n=10/IFL n=15 (cut-off 4.9%), 
TA NIFL n=18/IFL n=7 (cut-off 8.1%). Due to the high number of patients with in-
creased fat levels in the GCL and GCM muscles, the number of included spectra in the 
NIFL was lower compared to the other muscles. In addition, for the GCM muscle 11 
spectra and seven spectra for the GCL muscle did not meet our quality control criteria 
and therefore were not included in the analysis. In healthy controls all the acquired 
spectra were included in the analysis.
For the whole group of BMD patients PDE/ATP ratios were significantly increased 
compared to healthy controls in all five lower leg muscles. In the NIFL BMD group 
PDE/ATP ratios were significantly increased compared to healthy controls in the PER, 
SOL and TA muscles, except for a trend in the GCL (p=0.071) and no significant change 
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in the GCM (p=0.404) (Figure 4). The IFL BMD subgroup showed significantly in-
creased PDE/ATP ratios compared to healthy controls in all lower leg muscles. Values 
of Pi/ATP, Pi/PCr and PCr/ATP showed no significant differences between the whole 
group of BMD patients and healthy controls, except for an increase in the Pi/ATP ratio 
in the PER muscle of BMD patients. 
table 1. Patient parameters. 
Patient Age 
(years)
Mutation Age of first 
symptoms
Disability non-increased fat levels 
muscles
1 56 Unknown* 35 Mild PER, TA
2 48 Del45-48 14 Moderate None
3 49 Del45-48 10 Moderate None
4 29 Exon 19 
c.2380+3A>C ** 4
Severe None
5 51 Del45-55 6 Mild PER, SOL, TA
6 63 Del45-55 40 Mild TA
7 30 p1172X 4 Mild TA
8 26 Del45-47 9 No motor symptoms GCL, GCM, PER, SOL, TA
9 38 Exon 29 
p.Arg131>X *** None
No motor symptoms GCL, GCM, PER, SOL, TA
10 24 Del30-44 12 Mild TA
11 63 Del45-47 10 Severe None
12 33 Del03-05 None Mild TA
13 66 Dup14-42 6 Moderate None
14 39 Del45-47 6 Mild None
15 37 Del45-47 3 Moderate SOL, TA
16 20 Del45-47 None No motor symptoms GCL, GCM, PER, SOL, TA
17 29 Del45-47 12 Mild PER, TA
18 39 Del45-47 15 Mild TA
19 31 Del03-04 18 Moderate PER, SOL, TA
20 25 Del48-49 Floppy infant No motor symptoms GCL, GCM, PER, SOL, TA
21 37 Del03-04 3 Moderate TA
22 33 Del45-47 3 Mild GCL, SOL, TA
23 42 Del48-49 6 No motor symptoms  PER, SOL, TA
24 43 Del45-47 4 Moderate None
25 31 Del45-47 2 Mild GCL, GCM, PER, SOL, TA
Disability is scored as no motor symptoms, mild (difficulty walking without the use of walking aid), 
moderate (use of walking aid) or severe (wheelchair dependent). The muscles with non-increased fat 
fractions as compared to healthy controls are shown for each patient (medial and lateral head of gastroc-
nemic muscle (GCL and GCM), soleus (SOL), peroneus (PER) and anterior tibialis (TA)).(*No mutation 
could be found, patient had been found to have 62% dystrophin. **As a result of this mutation a large 




Controls BMD total BMD nIFl BMD IFl
n=14 n=18 n=5 n=13
Pi/ATP 0.34±0.02 0.40±0.02 0.37±0.04 0.41±0.03
Pi/PCR 0.10±0.01 0.10±0.01 0.09±0.016 0.11±0.01
PDE/ATP 0.19±0.03 0.34±0.03* (p=0.001) 0.288±0.051 0.36±0.03* (p=0.001)
PCr/ATP 3.59±0.12 3.54±0.11 3.842±0.204 3.4±0.13
pH 7.02±0.01 7.05±0.01*(p=0.017) 7.05±0.014 7.06±0.01*(p=0.017)
GCM n=14 n=14 n=5 n=9
Pi/ATP 0.38±0.03 0.44±0.03 0.42±0.04 0.45±0.03
Pi/PCR 0.10±0.05 0.18±0.05 0.11±0.08 0.22±0.06
PDE/ATP 0.25±0.04 0.34±0.04*(p=0.046) 0.27±0.06 0.38±0.05*(p=0.036)
PCr/ATP 3.82±0.16 3.77±0.16 3.81±0.27 3.76±0.20
pH 7.02±0.01 7.05±0.01*(p=0.025) 7.04±0.01 7.05±0.01*(p=0.033)
PeR n=14 n=25 n=10 n=15
Pi/ATP 0.32±0.03 0.40±0.02*(p=0.016) 0.36±0.03 0.43±0.03*(p=0.005)
Pi/PCR 0.09±0.01 0.11±0.006 0.11±0.01 0.12±0.01*(p=0.035)
PDE/ATP 0.16±0.03 0.33±0.02*(p<0.001) 0.30±0.032*(p=0.003) 0.35±0.03*(p<0.001)
PCr/ATP 3.48±0.1 3.61±0.07 3.53±0.11 3.66±0.09
pH 7.01±0.01 7.02±0.01*(p=0.047) 7.02±0.01 7.02±0.01
sol n=14 n=25 n=10 n=15
Pi/ATP 0.38±0.02 0.40±0.02 0.40±0.03 0.40±0.024
Pi/PCR 0.11±0.01 0.12±0.01 0.13±0.011 0.11±0.01
PDE/ATP 0.21±0.03 0.34±0.02*(p=0.003) 0.33±0.04*(p=0.017) 0.34±0.03*(p=0.006)
PCr/ATP 3.57±0.11 3.65±0.08 3.52±0.13 3.73±0.10
pH 7.02±0.01 7.04±0.004*(p=0.006) 7.04±0.01 7.04±0.01*(p=0.006)
tA  n=14 n=25 n=18 n=7
Pi/ATP 0.35±0.03 0.37±0.02 0.40±0.02 0.29±0.036
Pi/PCR 0.10±0.01 0.10±0.01 0.11±0.01 0.09±0.01
PDE/ATP 0.17±0.04 0.30±0.03*(p=0.01) 0.30±0.03*(p=0.019) 0.30±0.05* (p=0.05)
PCr/ATP 3.66±0.12 3.53±0.1 3.71±0.102 3.06±0.16(p=0.005)
pH 7.00±0.01 7.02±0.01*(p=0.039) 7.01±0.01 7.02±0.01
table 2. Mean values ±SD for the different metabolites in healthy controls, the overall BMD group, 
BMD patients with non-increased fat levels (NIFL) and BMD patients with increased fat levels 
(IFL). Significant differences between patients and controls are marked with an asterisk (*) and for 
these p values are shown. (Pi = inorganic phosphate, PDE = phosphodiester, PCr = phosphocreatine, 
ATP=adenosine triphosphate. GCL/GCM= lateral and medial head gastrocnemius, PER= peroneus, 
SOL=soleus, TA=anterior tibialis).
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In the NIFL BMD group no significant differences were found for any of these me-
tabolites (Table 2). Therefore, the increase in Pi/ATP ratio in the PER of the overall 
BMD group is due to the IFL BMD group in which significant increases in the Pi/
ATP (p=0.005) and Pi/PCr (p=0.035) were found for the PER. There was a significant 
increase in tissue pH in the GCM, GCL and SOL muscle in the IFL group, as well as in 
all muscles of the whole BMD group. Additionally there was a significant correlation 
between the fat fraction and PDE/ATP ratio in the BMD patients (R=0.20, p=0.04), but 
not in healthy controls (R=-0.02, p=0.9) (Figure 5).
Figure 4. Mean phosphodiester (PDE) in medial and lateral gastrocnemic muscle (GCL and GCM), 
peroneus (PER), soleus and anterior tibialis (TA) in healthy controls (black), BMD patients with non-
increased fat levels (NIFL) (white) and BMD patients with increased fat levels (IFL) (grey). 
Ratios significantly higher in BMD NIFL compared to controls are shown with an asterix (*) and signifi-
cantly higher in BMD IFL compared to control with a square (•). P values are as follows: for the NIFL 
BMD group (GCL p= 0.071, GCM p= 0.404, PER p= 0.003, SOL p=0.017 and TA p=0.019) and in the 
IFL BMD group (GCL p=0.001, GCM p=0.036, PER p<0.001, SOL p=0.006 and TA p=0.05).
Figure 5. Correlation between PDE/ATP ratios and fatty infiltration in BMD patients (grey dots) and 
healthy controls (black dots). 
For BMD patients there is a low, but significant correlation (R=0.20, p=0.04), however in the higher fat 




In this study we used a combination of quantitative proton MRI and localized 31P MR 
spectroscopy to evaluate high-energy phosphate levels in five lower leg muscles of 
BMD patients. In BMD patients the SOL, PER and TA with non-increased fat fractions 
and all muscles with increased fat fractions showed increased PDE/ATP ratios. This 
suggests that 31P MRS can be used to detect changes muscles of BMD patients before 
the onset of potentially irreversible changes like fatty infiltration.
The PDE signal in the MR spectrum is derived from glycerol 3-phosphocholine (GPC) 
and glycerol 3-phosphoethanolamine (GPE) which are thought to be membrane phos-
pholipids breakdown products [210, 211]. Slow-twitch, oxidative type 1 fibers have 
been shown to have higher PDE/ATP ratios and PDE has also been shown to increase 
with age [212, 213]. In addition, GPCs have been suggested to have some regulatory 
effects [214-217]. In muscular dystrophies increased PDE/ATP ratios have been found 
in Golden Retriever muscular dystrophy (GRMD) dogs, in Duchenne muscular dystro-
phy (DMD) patients, and in moderately affected BMD patients [95, 96, 112, 201, 218]. 
Our results are in agreement with these studies, although we did not find an increase in 
PDE/ATP ratio in the GCM and a trend in the GCL muscle. However, as we only had 
five data points in the NIFL group in these muscles, this could have resulted from a 
failure to reach statistical significance for these muscles. On the other hand, the SOL, 
PER and TA have a higher percentage of type 1 muscle fibers, and it could be that they 
are in some way affected differently by the ongoing membrane damage [210, 219]. As 
dysfunctional or absent dystrophin results in muscle membrane instability the elevated 
PDE/ATP ratios may also directly reflect membrane damage [220]. This is supported 
by the fact that in facioscapular muscular dystrophy (FSHD), a muscular dystrophy 
with no primary membrane damage, increased PDE/ATP ratios were only found in 
patients with increased fat levels [221]. However, the finding that in DMD patients 
fast, glycolytic type 2 fibres are preferentially affected could give some support the 
theory of a more regulatory role of PDE [112, 214, 217].
In previous studies where 31P MRS was applied in BMD patients only the (posterior) 
calf muscles of mild to moderately affected patients were scanned, without direct 
comparison with imaging data. As a result, no data were available on muscles without 
fatty infiltration and it was not clear if changes in phosphorous signals were already 
present before the onset of fatty infiltration. This is important, as PDE/ATP ratios have 
been shown to be adaptable in some conditions, whereas substitution of adipose tissue 
by muscle fibers has to our knowledge never been reported [110, 203-205, 222]. As it 
is likely that increased PDE/ATP ratios are to some extend related to muscle membrane 
damage, they could potentially be a marker for therapy efficacy if therapies preventing 
the membrane damage become available.
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The GCM, GCL and SOL with IFL showed a more alkaline pH than controls, which is 
in accordance with results of mild to moderately affected BMD patients from previous 
studies [92, 200, 201]. When evaluating the whole BMD group an increased pH was 
found for all investigated muscles. The cause for the increased pH, although frequently 
observed in BMD and DMD patients, is unclear. Possibly factors related to mitogen-
esis or an altered sarcolemmal proton efflux mechanisms ion transport are involved 
[95, 223].
We found no consistent changes in Pi/ATP or PCr/ATP ratios in the investigated mus-
cles. The fact that we did not find an increased Pi/ATP ratio and decreased PCr/ATP 
ratio in gastrocnemic muscles as reported in some previous studies could be related to 
the fact that we had to discard some of the spectra of severely affected patients, as they 
were of insufficient quality to analyse [92, 224]. This may have somewhat biased our 
results with regards to these muscles.
Our study has some limitations, as mentioned above we had to discard some of the 
spectra of the gastrocnemic muscles of BMD patients as they were of insufficient qual-
ity to be used for the analysis. This could have resulted in a bias with regards to the 
findings in the more severely fatty infiltrated gastrocnemic muscles and possibly be 
an explanation why no significant abnormalities were found in Pi/ATP and PCr/ATP 
ratios in these muscles. Secondly the NIFL groups for the gastrocnemic muscles were 
relatively small compared to the control group. As these muscles are the most severely 
affected in the lower leg of BMD patients this is not unexpected, however, it might 
have influenced the findings in terms of PDE levels and possibly the other metabolites 
in these muscles. Thirdly, the use of a 2D-CSI sequence instead of 3D could potentially 
result in a voxel spanning different muscles along the length of the leg. To circumvent 
this problem the 2D-CSI spectroscopy grid was carefully planned so that one voxel of 
each of the analysed muscles was located within the specific muscle, as demonstrated 
in Figure 1. If it was not possible to allocate the voxel solely to a specific muscle, due 
to the muscle being too small, the voxel was positioned in such a way that either air or 
bone (tissue from which no phosphor signal could be obtained) was included. Finally, 
the 7T fat fractions were not corrected for relaxation effects, which could have affected 
the exact fat percentage. However, as fat percentages were calculated using the exact 
same procedure for patients and age-matched controls, values of healthy controls were 
used for a muscle specific cut-off value and 3T and 7T values showed a high correla-
tion, this is not likely to have significantly influenced our results.
In conclusion, our results show that MR spectroscopy can detect increased PDE/ATP 
ratios in lower leg muscles of BMD patients prior to fatty infiltration. Therefore, PDE/
ATP ratios could be a useful parameter in the follow-up of muscle membrane damage 


















































Conclusion and general discussion
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ConClusIon AnD GeneRAl DIsCussIon
In the last decade the interest in MRI and MRS studies in DMD patients, and to a 
lesser extent in BMD patients, has increased substantially. The ability to quantitatively 
assess various aspects of the affected muscle makes MRI and MRS potentially use-
ful tools in the assessment of disease severity and progression. The development of 
future therapies for DMD patients has made such tools of increasing importance. So 
far the focus of many studies has been on the pattern in which the muscles are affected, 
the quantification of the fatty infiltration in the muscle and its relation with muscle 
strength and function and the relation with age [98, 101, 102, 104-106, 109, 140, 225]. 
Additionally some studies have described techniques to evaluate oedema in muscle 
and others applied proton and phosphorous MRS to study muscle metabolites [103, 
108, 111-115, 225]. As DMD and BMD are the most common muscle diseases with 
a limb-girdle pattern of weakness, and genetic testing is readily available, MRI and 
MRS are generally not necessary to reach a diagnosis. However, MR techniques could 
contribute to the evaluation of disease progression and future therapies.
In terms of disease progression, a striking feature in dystrophinopathy patients is the 
progressive decline of muscle function and muscle tissue. The muscles show increas-
ing amounts of fatty infiltration, although not all muscles become affected at the 
same moment or at the same rate. Our studies, and those of others, have shown that 
MRI can be used to quantify the fatty infiltration in multiple muscles and that these 
values are compatible with clinical features. We have shown that quantification of the 
fatty infiltration is more sensitive to subtle changes and shows less variability than 
semi-quantitative, visual scoring methods. Additionally we have shown that in DMD 
patients and in a homogeneous group of BMD patients, fatty infiltration increases with 
age and correlates with muscle function. A drawback of the use of fatty infiltration as 
outcome parameter is that fat is often regarded as an ‘end-point’ of the disease process 
and has so far not been shown to be reversible. Additionally, therapies currently under 
development aim to slow disease progression, rather than reverse pathology. Therefore 
evaluating the rate at which muscles become fat infiltrated could be a useful outcome 
parameter. If strength of muscle tissue were to improve, even with unchanged amounts 
of fatty infiltrated muscle, parameters such as the specific strength, described in chapter 
2 would be useful to evaluate such effects.
As outcome parameter the muscle T2 relaxation time as indicator of oedema/inflam-
mation in the muscle is more likely to be reversible in DMD patients than parameters 
such as the fatty infiltration [226]. In this thesis we described that the muscle T2 
relaxation times in DMD patients were increased, while no such increase was found in 
BMD patients. This suggests that increased muscle T2 relaxation times as indicator of 
inflammation/oedema are associated with the severity of the muscle damage. If so, the 
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T2 relaxation time could be a valuable outcome parameter. Unfortunately, increased 
levels of fatty infiltration complicate consistent measurement of T2 relaxation times in 
dystrophic muscle, as the T2 relaxation time of lipids is much longer than the skeletal 
muscle water T2 relaxation time. A possible method to overcome this problem is by us-
ing fat suppression. However, complete fat saturation is technically very complicated 
to achieve [227]. Separate assessment of the water and lipid signal would be another 
method to overcome this problem. This remains technically challenging in the whole 
muscle, but the recently described tri-exponential model, which can be used to asses 
both the T2 relaxation time independent of the fatty infiltration and to quantify the 
fat fraction is a promising alternative [183, 228]. As previous studies have suggested 
changes of the muscle energy metabolism we studied the phosphorous metabolism in 
muscles of BMD patients. We established that in BMD patients there was an increase 
in PDE/ATP ratio, before an increase in fat levels became apparent. As such the PDE/
ATP ratio could also be a useful parameter to assess muscle damage in early stages of 
the disease in BMD patients, but possibly also in DMD patients.
Other, so far not yet implemented in DMD or BMD patients, MR techniques could 
potentially also be of value as outcome parameters. Such techniques include diffusion 
tensor imaging for the assessment of the muscle fibre architecture and arterial-spin 
labelling for the evaluation of the tissue perfusion [229].
So far little is known of the value of the discussed methods in terms of therapy as-
sessment, since it is uncertain to what extent there will be changes in the muscle with 
appropriate therapy and how this will vary between differently affected muscles. Nev-
ertheless, as MR techniques can be used to assess different properties of the muscle it 
is likely that MRI and MRS can contribute in the evaluation of disease progression. 
Currently clinical trials use outcome measures such as the 6-minute walking test as 
outcome parameter. Although the relation between muscle strength and muscle tissue 
obtained with MRI has been shown to be significantly lower in DMD patients only one 
study so far has shown a relation between the mean fat fraction and ambulation in these 
patients [230]. However, it is likely that functional benefits of therapeutic approaches 
take longer to become apparent than subtle changes such as a decreased inflamma-
tory response or increase in strength of the muscle tissue. Therefore finding a method 
which can be used to quantify both the fatty infiltration and muscle T2 relaxation 
time while accounting for the fat, especially when combined with the quantitative 
strength measurements, could provide a detailed overview of ongoing damage and 






























































Muscle MRI and MRS are increasingly being implemented as diagnostic tool, param-
eter of disease severity and in the follow-up of neuromuscular disorders. Over the 
years several MR techniques have become available that could be of use in the assess-
ment of various characteristic parameters such as increased levels of fatty infiltration)
of these disorders Muscles of both DMD and BMD patients show signs of oedema, 
fatty infiltration and fibrosis and possibly an altered muscle energy metabolism. The 
aim of this thesis was to evaluate several MR methods that could serve as potential out-
come parameters in the assessment of muscle pathology in DMD and BMD patients. 
In Chapter 2 we compared the visually scored (semi-quantitative) amount of fatty 
infiltration with quantitative values obtained using 3-point Dixon MRI, a chemical 
shift-based water-fat separation method. We showed that in muscle with low fat frac-
tions visually scored values correlated well with their quantitative equivalents, but 
overall overestimated the amount of fatty infiltration. The quantitatively obtained fat 
fractions also showed less variability, especially in the more severely affected muscles 
and as such are more sensitive to subtle changes. Additionally we demonstrated that 
implementation of a multipeak model to account for the multiple peaks of the lipid 
spectrum in the 3-point Dixon method provided an even more accurate measurement 
of the fat fraction. We used the 3-point Dixon technique to evaluate the non-contractile 
and contractile (muscle without fatty infiltration) cross-sectional area in two upper 
and two lower leg muscle groups of DMD patients in Chapter 3 and combined these 
values with quantitative strength measurements. We demonstrated that the process of 
muscle hypertrophy and increasing levels of fatty infiltration appear to be two distinct 
processes, as the rate of progression differed between the investigated muscle groups. 
Additionally, we showed that a combination of quantitative MRI and strength mea-
surements could give an indication of muscle quality. As such, we demonstrated that 
the muscle strength in relation to the amount of contractile tissue is severely reduced 
in DMD patients. Thus, DMD patients need more muscle tissue to generate the same 
force. In Chapter 4 we applied the 3-point Dixon technique amongst other methods 
to explore the relation between dystrophin levels and fatty infiltration in the lower leg 
muscles (as indicator of disease severity) of a group of BMD patients. No such relation 
could be found, but there was a clear correlation between levels of fatty infiltration 
and age in a subgroup of patients with an exon 45-47 mutation. This indicated that the 
location of the mutation, and not the amount of dystrophin, is a major determinant of 
disease severity in these BMD patients. In Chapter 5 we measured the T2 relaxation 
times of muscle as marker of oedema/inflammation in DMD and BMD patients com-
pared to healthy controls, after adjustment for the fatty infiltration obtained with Dixon 
MRI. We showed that the T2 relaxation times were increased in DMD patients, but not 
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in BMD patients and as such could be useful as outcome parameter in trials aiming 
to ameliorate the DMD to a BMD phenotype. In addition to MRI, MRS methods like 
phosphorous MRS can be used to investigate energy metabolism in the muscle. In 
Chapter 6 we used a combination of 31P MRS and Dixon MRI at high magnetic field to 
show that PDE/ATP ratios were increased in lower leg muscles of BMD patients prior 
to the onset of fatty infiltration. The other metabolites showed no consistent changes 
in the investigated muscles, although there was an increase in tissue pH in the more 
severely affected muscles, with increased fat levels. These findings suggest that 31P 









Spier MRI en MRS worden in toenemende mate geïmplementeerd in de diagnostiek, 
als parameter van ziekte ernst en in het vervolgen van neuromusculaire ziekten. De 
afgelopen jaren zijn verschillende MR technieken beschikbaar gekomen welke zouden 
kunnen worden gebruikt in de evaluatie van verschillende karakteristieke parameters 
van de verschillende neuromusculaire ziekten zoals een toename van de vervetting 
in de skelet spieren. Zowel in DMD als in BMD worden er tekenen van oedeem, 
vervetting, fibrose en mogelijk veranderingen in het energie metabolisme in de spieren 
van patiënten geobserveerd. Het doel van dit onderzoek was om verschillende MR 
technieken te evalueren die mogelijk als uitkomstmaat gebruikt kunnen worden in de 
evaluatie van spieren van DMD en BMD patiënten. In hoofdstuk 2 hebben we een 
visueel gescoorde (semikwantitatieve) schaal gebruikt om de vervetting in spieren van 
DMD patiënten te scoren en de vet waarden verkregen met deze schaal vergeleken 
met een kwantitatieve 3-punts Dixon MRI techniek. We hebben aangetoond dat in 
spieren met weinig vervetting de visuele score goed overeenkwam met de kwantitatief 
verkregen waarde. Echter, in het algemeen werd met de visuele scoringsmethode de 
vetfractie overschat in vergelijking met de kwantitatief gescoorde vetfracties. Tevens 
waren de kwantitatieve waarden minder variabel, voornamelijk in de meer ernstig 
aangedane spieren, en meer sensitief voor subtiele veranderingen. Aanvullend hebben 
we aangetoond dat met implementatie van een multipeak model, om te corrigeren voor 
de verschillende pieken van het vetsignaal bij het gebruiken van de 3-punts Dixon 
techniek, het vetsignaal meer nauwkeurig kon worden bepaald. In hoofdstuk 3 hebben 
we de 3-punts Dixon techniek gebruikt om het contractiele (niet vervette spier) en 
niet-contractiele cross-sectionele oppervlakte van de spier te berekenen in 2 spiergroe-
pen in zowel het boven- als onderbeen. Deze waarden hebben we gecombineerd met 
de kracht per spiergroep die kwantitatief is gemeten. Hierbij hebben we aangetoond 
dat het proces van spierhypertrofie en toename van vervetting in de spier 2 verschil-
lende processen zijn, aangezien de snelheid waarmee de veranderingen optreden in de 
spiergroepen per proces verschillend zijn. Aanvullend hebben we aangetoond dat een 
combinatie van kwantitatieve MRI en krachtmetingen een indicatie kan geven van de 
spierkwaliteit. Door deze twee technieken te combineren konden we demonstreren 
dat de kracht die gerelateerd is aan de hoeveelheid contractiel weefsel per spiergroep 
ernstig is afgenomen in DMD patiënten, en dat deze patiënten meer spierweefsel 
nodig hebben om dezelfde hoeveelheid kracht te leveren. In hoofdstuk 4 hebben we 
de 3-punts Dixon techniek in combinatie met andere methoden gebruikt om de relatie 
tussen dystrofine en vervetting in spieren in het onderbeen (als maat van de ernst van 
de ziekte) te bepalen in BMD patiënten. We konden geen relatie aantonen tussen de 
vervetting in de spieren en de hoeveelheid dystrofine maar er was wel een significante 
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relatie tussen de leeftijd van patiënten met dezelfde mutatie (exon 45-47 mutatie) en 
de hoeveelheid vervetting. Deze bevinding is een indicator dat de plek van de mutatie, 
en niet zozeer de hoeveelheid dystrofine, een belangrijke determinant is van de ernst 
van de ziekte van patiënten met de ziekte van Becker. In hoofdstuk 5 hebben we de 
T2 relaxatie tijd, als parameter voor ontsteking in de spier, in DMD en BMD patiënten 
gemeten en vergleken met gezonde controles, nadat de waarden zijn ‘gecorrigeerd’ 
voor de vervetting in de spieren, welke de T2 waarden beïnvloed. We hebben in dit 
hoofdstuk aangetoond dat de T2 relaxatie tijd in spieren van DMD patiënten is ver-
hoogd, maar dat dit niet zo is in de spieren van BMD patiënten. Dit zou erop kunnen 
wijzen dat de T2 relaxatie tijd als uitkomstmaat gebruikt zou kunnen worden in trials 
waar het doel is het DMD fenotype te veranderen in het BMD fenotype. In aanvulling 
op de verschillende MRI methoden die gebruikt zijn kan MR spectroscopie (MRS) 
worden gebruikt om het energie metabolisme in de spier te onderzoeken. In hoofdstuk 
6 hebben we een combinatie van fosfor (31P) MRS en Dixon MRI gebruikt op hoge 
veldsterkte en aangetoond dat PDE/ATP ratio’s verhoogd zijn in onderbeen spieren van 
BMD patiënten en dat deze verandering al aanwezig is voordat er vervetting optreedt 
in de spieren. Voor de andere onderzochte metabolieten konden geen consistente ver-
anderingen worden gevonden in de spieren die onderzocht zijn. In spieren met ernstige 
vervetting werd wel een verhoging van de pH in de spier gevonden. Deze bevindingen 
suggereren dat 31P MRS een waardevolle aanvulling kan zijn om veranderingen vroeg 
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ANCOVA Analysis of covariance
ATP  Adenosine triphosphate
BMD  Becker muscular dystrophy
CRLB  Cramér-Rao Lower Bound
CSA  Cross sectional area
CT  Computed tomography
DGC  Dystrophin-glycoprotein complex
DMD  Duchenne muscular dystrophy
EDL  Extensor digitorum longus muscle
FIB  Fibularis muscle
FOV  Field of view
GCL  Lateral gastrocnemius muscle
GCM  Medial gastrocnemius muscle 
GPC   Glycerol 3-phosphocholine
GPE  Glycerol 3-phosphoethanolamine
IFL  Increased fat levels
MRI  Magnetic resonance imaging
MRS  Magnetic resonance spectroscopy
MVIC  Maximal voluntary isometric contraction
NIFL  Non-increased fat levels
nNOS  Neuronal nitric oxide synthase
NO  Nitric oxide
TA  Anterior tibialis muscle
TE  Echo time
TP  Posterior tibialis muscle
TSE  Turbo spin-echo
TR  Repetition time
PCr  Phosphocreatine
PDE  Phosphodiesterase
PER  Peroneus muscle
Pi  Inorganic phosphate
S  Sartorius muscle
SD  Standard deviation
SE  Spin echo
SOL  Soleus muscle
SPAIR  Spectral pre-saturation with inversion recovery
ROI  Region of interest
QMA  Quantitative muscle assessment
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